SEARCH
Search Details
Kitagataya Takashi
| Hokkaido University Hospital Internal Medicine Gastroenterology and Hepatology | Specially Appointed Assistant Professor |
Researcher basic information
■ Degree■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
- 70989631
Research Field
Career
■ CareerCareer
- Jul. 2023 - Present
Hokkaido University, Hokkaido University Hospital, 特任助教 - Apr. 2022 - Jun. 2023
Mayo Clinic, Department of Gastroenterology and Hepatology, Postdoctoral Research Fellow, United States - Apr. 2019 - Mar. 2022
Hokkaido University, 消化器内科, 医員 - Apr. 2018 - Mar. 2019
苫小牧市立病院, 消化器内科, 医員 - Apr. 2017 - Mar. 2018
市立函館病院, 消化器内科, 医員 - Apr. 2016 - Mar. 2017
北海道医療センター, 消化器内科, 医員 - Apr. 2014 - Mar. 2016
製鉄記念室蘭病院, 初期研修医
Research activity information
■ Awards- Jun. 2026, 日本肝臓学会, 研究奨励賞
- Apr. 2026, Asian Pacific Association for the Study of the Liver, APASL Oncology 2026 Tokyo Young Investigator Award
- May 2025, European Association for the Study of the Liver, EASL Congress 2025 Young Investigator Award
- Nov. 2016, 日本内科学会, 第278回日本内科学会北海道地方会最優秀若手奨励賞(後期研修医の部)
北潟谷隆
- Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.
Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Daisuke Yokoyama; Shoichi Kitano; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
Journal of cachexia, sarcopenia and muscle, 17, 3, e70305, Jun. 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Cachexia and sarcopenia are prevalent, inflammation-linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined. In this study, we evaluated the prevalence, clinical features and prognostic impact of cachexia and sarcopenia-alone and combined-in chronic liver disease. METHODS: We retrospectively screened 776 patients with liver cirrhosis (LC) and/or hepatocellular carcinoma (HCC) at Hokkaido University Hospital (August 2014-May 2025). The inclusion criteria were grip strength, CT-based muscle mass and complete clinical data, yielding 307 patients; 469 did not meet one of the inclusion criteria. Cachexia was determined following the Asian Working Group for Cachexia criteria, and sarcopenia was determined following Japan Society of Hepatology guidelines. Patients were grouped as no cachexia/sarcopenia, cachexia only, sarcopenia only or cachexia+sarcopenia. The outcomes were overall survival, time to liver-related events and time to readmission (Kaplan-Meier and Cox-proportional models). RESULTS: Among 776 patients, 307 were included in the final-analysis. Of 307 patients, 206 (67.1%) were male, the median age was 70 years (range, 19-90 years), 262 patients (85.3%) had LC and 188 patients (61.2%) had HCC. The patients were grouped as no cachexia/sarcopenia (213; 69.4%), cachexia only (54; 17.6%), sarcopenia only (17; 5.5%) and cachexia+sarcopenia (23; 7.5%). The combined group compared with the others had the lowest body mass index, psoas-muscle-index and grip strength (all p < 0.001). Overall survival (OS), liver-related events, LC progression and readmissions were compared between 246 patients with and without cachexia or sarcopenia, after excluding those who visited the hospital on or after July 2023 and had ≤ 3 months of follow-up. OS was shorter in the cachexia only (median 61.8 [95% CI 40.90-not reached (NR)] months, p = 0.046) and cachexia+sarcopenia (median 59.6 [95% CI 14.26-NR] months, p = 0.027) groups than in the no cachexia/sarcopenia group. Multivariable analysis showed that cachexia+sarcopenia (hazard ratio 2.48, p = 0.010), HCC (hazard ratio 3.40, p < 0.001) and diabetes mellitus (hazard ratio 1.80, p = 0.013) independently predicted mortality. The combined group compared with the other groups had a shorter time to liver-related events and readmission. CONCLUSIONS: The coexistence of cachexia and sarcopenia-rather than either alone-can be used as an indicator for identifying patients with chronic liver disease at the highest risk of poor outcomes. Concurrent assessment and early, targeted interventions may improve outcomes in this population. - Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.
Masato Nakai; Masatsugu Ohara; Daisuke Yokoyama; Shoichi Kitano; Takatsugu Tanaka; Naohiro Yasuura; Akimitsu Meno; Takashi Kitagataya; Takuya Sho; Goki Suda; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 56, 4, 505, 514, Apr. 2026, [International Magazine]
English, Scientific journal, AIM: In patients with decompensated liver cirrhosis, water retention often leads to complications such as acute kidney injury and poor prognosis. Soluble CD14 (sCD14), a marker of bacterial translocation, may have clinical relevance in this setting. Therefore, we aimed to investigate the prognostic value of sCD14 in patients with decompensated liver cirrhosis and water retention, and to determine its association with diuretic responsiveness, acute kidney injury development, and short-term mortality. METHODS: We retrospectively analyzed 134 patients with decompensated liver cirrhosis and refractory fluid retention treated with tolvaptan. Associations between serum sCD14 levels and diuretic response, acute kidney injury development, and liver-related mortality were evaluated. sCD14 was compared with other bacterial translocation markers (soluble CD163 and mannose receptor) in a subset excluding patients with advanced hepatocellular carcinoma. RESULTS: Lower sCD14 levels were associated with improved short- and long-term diuretic responses and a lower acute kidney injury incidence. Patients with sCD14 ≤ 2340 pg/mL had significantly better liver-related survival than those with higher levels (median survival time: 24.5 vs. 4.8 months, respectively; p < 0.01). In the multivariate analysis, sCD14 > 2340 pg/mL independently predicted liver-related mortality (hazard ratio = 2.71, p < 0.01). Compared with sCD163 and mannose receptor, sCD14 demonstrated superior prognostic value. Concomitant rifaximin use was significantly associated with lower sCD14 levels. CONCLUSIONS: sCD14 is a potential biomarker for predicting prognosis, diuretic response, and acute kidney injury development in patients with decompensated liver cirrhosis and water retention. Its predictive capacity surpasses that of other bacterial translocation markers and may be influenced by administering therapeutic interventions, including rifaximin. - Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.
Goki Suda; Masatsugu Ohara; Masaru Baba; Yoshiya Yamamoto; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Hidetaka Hosono; Daisuke Yokoyama; Shoichi Kitano; Takatsugu Tanaka; Akimitsu Meno; Naohiro Yasuura; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Osamu Maehara; Shunsuke Ohnishi; Takaaki Izumi; Ren Yamada; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Izumi Tsunematsu; Naoya Sakamoto
The Journal of infection, 92, 4, 106715, 106715, Apr. 2026, [International Magazine]
English, Scientific journal, OBJECTIVE: Our prior interim report remains the only prospective study evaluating tenofovir alafenamide (TAF) for HBV reactivation prevention, with prophylaxis assessed up to 12 months. Herein, we report the final 24-month follow-up results. METHODS: This multicentre prospective-study enrolled HBV carriers who received prophylactic TAF before antineoplastic or immunosuppressive therapy and patients with resolved HBV infection who developed reactivation and received TAF as reactivation-related hepatitis prophylaxis. We examined TAF effectiveness at 12 and 24 months. The primary endpoints were HBV reactivation and reactivation-related hepatitis. RESULTS: Of 191 enrolled patients, 150 and 127 were evaluable at 12 and 24 months, respectively. At 12 months, no HBV reactivation, HBV reactivation-related hepatitis, or therapy interruption occurred. Between months 12-24, four patients discontinued TAF. None of the remaining patients experienced HBV reactivation, HBV reactivation-related-hepatitis, or treatment interruption. Virologic relapse occurred in one of two patients with TAF discontinuation after anticancer/immunosuppressive therapy completion; TAF re-initiation enabled biochemical hepatitis prevention and viral suppression. Neither patient who switched to entecavir experienced reactivation. No patients on high-risk regimens developed reactivation, reactivation-related hepatitis, or treatment interruption. No patient discontinued therapy for TAF-related adverse events. CONCLUSIONS: Over 24 months, TAF demonstrated effectiveness in preventing HBV reactivation and reactivation-related hepatitis. - Genetic ablation of interleukin-17A augments fibrosis in a mouse model of cholestatic liver injury.
Takashi Kitagataya; Anuradha Krishnan; Kirsta E Olson; Florencia Gutierrez; Michelle Baez-Faria; Maria Eugenia Guicciardi; Kevin D Pavelko; Adiba I Azad; Gregory J Gores
PloS one, 21, 2, e0342251, 2026, [International Magazine]
English, Scientific journal, AIM: The underlying mechanisms contributing to cholestatic liver injury remain unclear. The pro-inflammatory leukocyte-restricted cytokine interleukin-17A (IL-17A) has been implicated in human cholestatic liver injury. However, mechanistic insights are lacking and require further exploration in preclinical models. Herein, we examined the effect of IL-17A genetic ablation in a mouse model of cholestatic liver injury. METHOD: Age and gender-matched littermate wild type (WT) and Il-17a-/- C57BL/6 mice were fed an intermittent 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet for 21 days to induce cholestatic liver injury or a control diet. RESULTS: As compared to WT littermates, Il-17a-/- mice displayed more abundant desmin-positive myofibroblasts and increased fibrosis. NanoString analysis of intrahepatic leukocyte populations using a fibrosis-related gene panel identified upregulation of Tnfsf14 (encoding the protein LIGHT) in the DDC-fed Il-17a-/- mice. Although mass cytometry identified an increase in myeloid cells in both genotypes of the DDC-fed mice, we could not identify LIGHT expression in this cell lineage. Instead, the upregulation of LIGHT expression was largely restricted to a CD4+ T cell population as assessed by flow cytometry. Enhanced LIGHT expression was observed in a Th1+ CD4+ T cell population. LIGHT activated primary human hepatic stellate cells in vitro, suggesting that LIGHT stimulation of hepatic fibrogenesis may be direct. CONCLUSION: Taken together, these data suggest that IL-17A restrains expression of the profibrogenic cytokine, LIGHT, by Th1-polarized CD4+ T cells, and implicate a role for LIGHT in cholestatic fibrogenesis in DDC-fed mice; a finding which requires validation in additional models. - Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.
Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
Frontiers in nutrition, 13, 1730695, 1730695, 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Cachexia is associated with poor prognosis in chronic liver disease (CLD), yet robust predictors remain poorly defined. This study examined clinical factors and serum biomarkers associated with cachexia in patients with CLD. METHODS: We analyzed 356 of 526 patients with CLD who had complete cachexia assessment and available stored serum samples. In a discovery cohort (n = 240; Aug 2014-Jun 2023), serum fibroblast growth factor 21 (FGF21), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured. Multivariable logistic regression and receiver operating characteristic analyses were used to identify independent predictors and optimal cutoff values. Findings were subsequently evaluated in an independent validation cohort (n = 116; Jul 2023-May 2025). RESULTS: Median age was 68 years (range 19-90), 65.8% of participants were male, and 24.6% had cachexia, which independently predicted worse overall survival (hazard ratio 1.64; 95% CI 1.03-2.62; p = 0.038). Patients with cachexia had higher serum FGF21 concentrations than those without cachexia (median, 292 vs. 177 pg./mL; p = 0.002), whereas IL-6 and TNF-α levels did not differ significantly between groups. FGF21 was the only biomarker independently associated with cachexia (odds ratio, 1.71; 95% CI, 1.10-2.66; p = 0.016). Advanced Child-Pugh class and platelet count were identified as additional independent clinical predictors. CONCLUSION: Serum FGF21 independently predicts cachexia in CLD and may facilitate earlier identification of at-risk patients, enabling timely intervention to improve clinical outcomes. - Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.
Goki Suda; Masaru Baba; Yoshiya Yamamoto; Sonoe Yoshida; Tetsuhito Muranaka; Takashi Meguro; Katsumi Terashita; Jun Ito; Tomoe Kobayashi; Takaaki Izumi; Tomofumi Takagi; Shunichi Hosoda; Ren Yamada; Qingjie Fu; Zijian Yang; Daisuke Yokoyama; Takatsugu Tanaka; Akimitsu Meno; Naohiro Yasuura; Takashi Kitagataya; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto
Scientific reports, 15, 1, 42628, 42628, 28 Nov. 2025, [International Magazine]
English, Scientific journal, Simplified ("minimal monitoring") pathways can expand access to direct-acting antivirals (DAAs) by reducing visit burden. In Japan, where hepatitis C virus (HCV) patients are among the oldest worldwide, whether DAA regimens can be delivered safely and effectively with fewer visits remains unclear, and real-world outcomes with sofosbuvir/velpatasvir are scarce. We evaluated effectiveness, safety, and visit frequency in a multicenter cohort. Sixty patients with HCV-infection, with or without compensated liver cirrhosis, received 12 weeks of sofosbuvir/velpatasvir with follow-up to sustained virologic response at 12 weeks post-treatment (SVR12). The visit number was set with no schedule and analyzed post hoc (≤ 3 vs. ≥4 visits). There were 1-8 outpatient visits (median 3). SVR12 was 96.7% by intention-to-treat (ITT; 58/60; 95% CI, 88.6-99.6) and 100% per protocol (57/57; 95% CI, 90.0-100.0). Cure rates were comparable (ITT 95.8-97.2% for ≤ 3 vs. ≥4 visits; p = 1.00; PP 100% in both). Sofosbuvir/velpatasvir was well-tolerated: adverse events were recorded in 10%, none grade ≥ 3, no treatment-related serious events, and no toxicity-related discontinuations. Two patients were lost to follow-up; one who discontinued treatment achieved SVR12. This is the first Japanese real-world evaluation of DAA under simplified monitoring and supports low-burden pathways with high efficacy and safety. - 肝硬変合併症(臓器相関を含む)の病態解明と最新治療(肝硬変) QTc延長が肝硬変症例の臨床経過に与える影響に関する検討
北潟谷 隆; 須田 剛生; 坂本 直哉
肝臓, 66, Suppl.3, A778, A778, (一社)日本肝臓学会, Oct. 2025
Japanese - Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.
Goki Suda; Masaya Sugiyama; Hayato Hikita; Akira Nishio; Tomohide Tatsumi; Tetsuo Takehara; Miyako Murakawa; Mina Nakagawa; Yasuhiro Asahina; Masashi Mizokami; Tatsuhiko Kakisaka; Yuzuru Sakamoto; Akinobu Taketomi; Koji Miyanishi; Yoshiyuki Ueno; Hiroaki Haga; Shinya Maekawa; Nobuyuki Enomoto; Masayuki Kurosaki; Motoyuki Kohjima; Makoto Nakamuta; Yasuhito Tanaka; Yoshiya Yamamoto; Masaru Baba; Hisatoshi Hanamatsu; Jun-Ichi Furukawa; Masatsugu Ohara; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto
Biomarker research, 13, 1, 113, 113, 24 Sep. 2025, [International Magazine]
English, A subset of patients still develops hepatocellular carcinoma (HCC) even after eradication of the hepatitis-C virus (HCV) by anti-HCV treatment. We conducted a genome-wide association study (GWAS) to identify host genetic factors associated with HCC development following HCV eradication in Japan. In this GWAS (n = 517), the discovery cohort included 118 patients without HCC and 67 who developed HCC following HCV eradication with interferon-based therapy. A genome-wide scan for HCC-associated variants was conducted. An independent cohort of 274 patients without HCC and 58 patients with post-eradication HCC was used for replication. The effects of candidate gene variants were assessed clinically and through in vitro cellular assays. The GWAS identified significant variants associated with HCC development following HCV eradication, including rs4778350, located near the long non-coding RNA Prader-Willi non-protein coding RNA 4 (PWRN4) on chromosome 15. In the combined analysis, rs4778350 remained significantly associated with HCC, showing a high odds ratio of 5.86 (95% CI, 3.63-9.44). The frequency of the A allele in rs4778350 differs across ethnic populations. Multivariate analysis revealed that female sex, high platelet count, and higher serum albumin levels were associated with reduced HCC risk, while fibrosis stage F4 and the AA genotype of rs4778350 were linked to increased risk. The AA genotype of rs4778350 enhanced PWRN4 expression, promoting cell proliferation, migration, and invasion. These findings suggest a role for PWRN4 in hepatocarcinogenesis through its association with rs4778350 in patients achieving HCV eradication. - 切除不能進行肝細胞に対するアテゾリズマブ+ベバシズマブ治療と局所療法併用のインパクト
荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 坂本 直哉
肝臓, 66, Suppl.2, A640, A640, (一社)日本肝臓学会, Sep. 2025
Japanese - Bacterial translocationマーカーによる腹水を有する非代償性肝硬変の利尿剤反応性と予後予測
中井 正人; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉
肝臓, 66, Suppl.2, A658, A658, (一社)日本肝臓学会, Sep. 2025
Japanese - Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Masatsugu Ohara; Goki Suda; Risako Kohya; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shinya Maekawa; Nobuyuki Enomoto; Makoto Chuma; Manabu Morimoto; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Atsumasa Komori; Yuki Kugiyama; Masaru Baba; Akihisa Nakamura; Jun Ito; Ren Yamada; Shunichi Hosoda; Yoshiya Yamamoto; Sonoe Yoshida; Takuya Sho; Takashi Sasaki; Tomoka Yoda; Akimitsu Meno; Naohiro Yasuura; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Koji Ogawa; Naoya Sakamoto
Hepatology international, 28 Aug. 2025, [International Magazine]
English, Scientific journal, BACKGROUND: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality. Although the atezolizumab/bevacizumab regimen demonstrated impressive efficacy in the IMbrave150 clinical trial, long-term outcomes, particularly 3-year overall survival (OS), remain unestablished because of limited follow-up. Long-term outcomes have been reported for the tremelimumab/durvalumab combination, highlighting the need for comparable data on atezolizumab/bevacizumab. We aimed to elucidate the 3-year OS in patients with unresectable HCC (uHCC) treated with atezolizumab plus bevacizumab. METHODS: This retrospective multicenter study included patients with uHCC who received atezolizumab/bevacizumab. Among the 506 patients treated at the participating institutions, only those who initiated therapy between October 2020 and January 2022 were included. Comprehensive clinical, laboratory, and imaging data were collected, and the patients were followed up until March 2025. RESULTS: A total of 257 patients were analyzed, with a median follow-up of 48.23 months (range, 36.23-53.60 months). The 2- and 3-year OS rates were 39.2% and 25.3%, respectively. Among patients meeting the IMbrave150 criteria, the 3-year OS rate was 31.6%. Multivariate regression analysis identified baseline alpha-fetoprotein level > 116 ng/mL (odds ratio [OR] 0.41; 95% confidence interval [CI] 0.20-0.84; p = 0.015) and modified albumin-bilirubin grade 1-2a (OR 2.50; 95% CI 1.18-5.32; p = 0.017) as significant factors associated with 3-year OS. CONCLUSIONS: In a real-world setting, the 3-year OS for uHCC patients treated with atezolizumab/bevacizumab was 25.3%, rising to 31.6% among those meeting the IMbrave150 criteria. Survival outcomes underscore the clinical value of atezolizumab/bevacizumab in improving long-term prognosis and guiding first-line treatment decisions for patients with unresectable HCC. - 慢性肝疾患におけるTPORAの有効性の検討 脾臓体積に注目して
中井 正人; 横山 大輔; 田中 崇倫; 北野 翔一; 保浦 直弘; 目野 晃光; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉
日本門脈圧亢進症学会雑誌, 31, 3, 161, 161, (一社)日本門脈圧亢進症学会, Aug. 2025
Japanese - Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes
Takashi Kitagataya; Goki Suda; Takatsugu Tanaka; Shoichi Kitano; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Qingjie Fu; Shunichi Hosoda; Sonoe Yoshida; Osamu Maehara; Shunsuke Ohnishi; Masatsugu Ohara; Masato Nakai; Takuya Sho; Kosuke Nakamura; Suguru Ishizaka; Naoya Sakamoto
Hepatology Research, 19 Jun. 2025, [International Magazine]
English, Scientific journal, AIM: Cirrhotic cardiomyopathy (CCM) is a significant complication of liver cirrhosis; however, its prevalence and impact in Asian populations remain unclear. The aim of this study was to assess the prevalence of CCM in Japanese patients with liver cirrhosis and to evaluate its impact on clinical outcomes. METHODS: In this retrospective study, 80 patients with liver cirrhosis confirmed using transient elastography (liver stiffness ≥ 12.5 kPa) were included. Study was performed at Hokkaido University Hospital between January 2014 and April 2024. CCM was diagnosed using the 2019 Cirrhotic Cardiomyopathy Consortium criteria. Subsequently, patient characteristics, survival, and the incidences of decompensation and cardiovascular events were analyzed. RESULTS: The prevalence of CCM was 46.3% (37/80), with 78.4% of patients with CCM showing isolated systolic dysfunction based on global longitudinal strain. Patients with CCM were significantly older, had lower serum ammonia and bilirubin levels, and had higher platelet counts. CCM was associated with a significantly higher incidence of decompensation events (hazard ratio 3.97, 95% confidence interval 1.64-9.61, p = 0.003) and was an independent risk factor for decompensation in the multivariate analysis (hazard ratio 3.24, 95% confidence interval 1.29-8.11, p = 0.012). Patients with and without CCM showed no significant differences in overall survival or cardiovascular events. CONCLUSIONS: CCM is prevalent among Japanese patients with liver cirrhosis and is associated with an increased risk of hepatic decompensation. These findings highlight the importance of cardiac evaluation in patients with cirrhosis and suggest that CCM should be considered in the management of liver cirrhosis to improve patient outcomes. - Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
Risako Kohya; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Takuya Sho; Makoto Chuma; Atsumasa Komori; Yuki Kugiyama; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Shinya Maekawa; Nobuyuki Enomoto; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
JHEP reports : innovation in hepatology, 7, 5, 101364, 101364, May 2025, [International Magazine]
English, Scientific journal, BACKGROUND & AIMS: Fibroblast growth factor 21 (FGF21) is a crucial regulator of cell metabolism. Tumour-secreted FGF21 has shown immune-checkpoint factor functions, and high FGF21 levels are associated with a poor prognosis for patients. However, its prognostic value and impact on treatment response in patients with hepatocellular carcinoma (HCC) treated with immune-checkpoint inhibitors (ICIs) remain unclear. Thus, this study investigated the potential of high FGF21 levels as a prognostic marker and whether traditional ICI-based therapy can improve the prognosis of patients with high FGF21 levels. METHODS: In this retrospective multicentre study, patients with unresectable HCC who received atezolizumab/bevacizumab in the NORTE study group (n = 117) were classified into high (≥915 pg/ml; n = 29) and non-high (n = 88) FGF21 groups. For validation, we investigated patients treated with atezolizumab/bevacizumab in an independent cohort (n = 285). Overall survival, progression-free survival, and treatment response were compared between patients with and without high baseline FGF21 levels. RESULTS: The median overall survival (p <0.001) and progression-free survival (p = 0.045) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. Independent cohort analysis validated these results. In the overall cohort, the median progression-free survival (5.75 vs. 8.84 months; p = 0.027) and median overall survival (14.13 vs. 22.08 months; p <0.001) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. The durable response (≥6 months) + complete response rate was significantly decreased in the high FGF21 group (p = 0.045). No patient with a high FGF21 level achieved a complete response, whereas this was achieved in 4.1% (13/319) of patients with non-high FGF21 levels. Multivariate Cox regression analysis identified high baseline serum FGF21 as an independent poor prognostic factor for overall survival (hazard ratio 2.20, p <0.001). CONCLUSIONS: Serum FGF21 may be a robust, non-invasive prognostic and treatment response marker for unresectable HCC treated with atezolizumab/bevacizumab. IMPACT AND IMPLICATIONS: FGF21 has been reported to act as a secreted immune-checkpoint factor, and elevated levels of FGF21 are associated with a poor prognosis in patients with HCC. It is not fully understood whether ICIs can overcome the impact of high FGF21 levels on the shortened prognosis of patients with HCC. In this multicentre retrospective study, patients with HCC and high baseline levels of serum FGF21 who received atezolizumab/bevacizumab treatment exhibited a significantly shorter overall survival and shorter progression-free survival. These findings suggest serum FGF21 as a robust prognostic marker and an indicator of treatment response in unresectable HCC treated with ICI-based therapy. These findings could be crucial for the implementation of personalised treatment strategies for unresectable HCC. However, identifying optimal therapeutic options for patients with unresectable HCC and high serum FGF21 levels remains an urgent and critical clinical issue. - 肝疾患基礎研究from bench to bedside,未来の肝臓病学を考える(1) IL-17A遺伝子欠損が胆汁うっ滞性肝疾患の病態に及ぼす影響の検討
北潟谷 隆; 須田 剛生; 坂本 直哉
肝臓, 66, Suppl.1, A208, A208, (一社)日本肝臓学会, Apr. 2025
Japanese - 肝内胆管癌との鑑別に難渋し手術加療にて診断が得られた肝偽リンパ腫の1例
田中 崇倫; 北潟谷 隆; 北野 翔一; 目野 晃光; 保浦 直弘; 佐々木 貴志; 甲谷 理紗子; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 柿坂 達彦; 種井 善一; 田中 伸哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 136回・130回, 65, 65, 日本消化器病学会-北海道支部, Mar. 2025
Japanese - 肝線維化・肝発癌における基礎と臨床の融合 慢性B型肝炎症例におけるCAMP-BとPAGE-Bによる発癌リスク評価の検討
大原 正嗣; 須田 剛生; 保浦 直弘; 目野 晃光; 甲谷 理紗子; 佐々木 貴志; 北潟谷 隆; 中井 正人; 荘 拓也; 坂本 直哉
日本消化器病学会雑誌, 122, 臨増総会, A212, A212, (一財)日本消化器病学会, Mar. 2025
Japanese - Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
Zijian Yang; Goki Suda; Takuya Sho; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Qingjie Fu; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Tomoe Kobayashi; Minhu Chen; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 55, 3, 433, 443, 25 Nov. 2024, [International Magazine]
English, Scientific journal, AIM: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear. We aimed to clarify these. METHODS: In this multicenter retrospective study, we screened patients with HCC treated with atezolizumab/bevacizumab. The prognostic impact of grade ≥2 proteinuria was examined in patients with proper clinical data and preserved serum for growth factor analysis. For biomarker analysis predicting proteinuria, baseline serum vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D levels were analyzed. RESULTS: This study included 75 patients, and 32 (42.7%) experienced grade ≥2 proteinuria. No significant differences were observed between those with or without proteinuria, except for aspartate transaminase and alanine transaminase levels. Time-dependent Cox proportional hazards analysis revealed that grade ≥2 proteinuria was significantly associated with better prognosis (hazard ratio 0.221; 95% confidence interval 0.082-0.592; p = 0.003). In biomarker analysis, low baseline serum VEGF-C and VEGF-D levels were significantly associated with proteinuria, and multivariate analysis demonstrated that baseline serum VEGF-D level was significantly associated with grade ≥2 proteinuria (hazard ratio 0.101; 95% confidence interval 0.029-0.357; p < 0.001). CONCLUSIONS: Grade ≥2 proteinuria in patients with unresectable HCC treated with atezolizumab/bevacizumab indicates a better prognosis, and baseline serum VEGF-D levels can help predict its occurrence. These findings can help in managing adverse events and prognosis in advanced HCC treated with atezolizumab/bevacizumab. - 切除不能肝細胞癌に対するレンバチニブ治療後のFGF21の変化と食欲不振の関連性について
甲谷 理紗子; 須田 剛生; 大原 正嗣; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉
日本消化器病学会雑誌, 121, 臨増大会, A802, A802, (一財)日本消化器病学会, Oct. 2024
Japanese - Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
Naohiro Yasuura; Goki Suda; Masatsugu Ohara; Akimitsu Meno; Takuya Sho; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Tomoya Saitou; Masaya Sugiyama; Takasuke Fukuhara; Masaru Baba; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Akinobu Taketomi; Naoya Sakamoto
Alimentary pharmacology & therapeutics, 60, 10, 1315, 1324, 04 Sep. 2024, [International Magazine]
English, Scientific journal, BACKGROUND AND AIMS: The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these patients remain unclear. We aimed to close these gaps. METHODS: We retrospectively screened patients with newly diagnosed non-HBV-related-HCC (standard HBsAg-test negative) at Hokkaido University. Patients with complete clinical information and preserved serum for hHBsAg+ were included. We evaluated the prevalence, characteristics and prognostic impact of pHBV and hHBsAg+ in non-HBV-related-HCC. RESULTS: A total of 401 non-HBV-related-HCC patients were included (288 with pHBV/113 without pHBV). In non-HBV-related-HCC, pHBV did not affect overall survival (OS). Among non-HBV-related-HCC patients with pHBV, 11.8% (34/288) were hHBsAg+ and had more advanced stages of HCC, higher AFP levels, higher vascular invasion rates, and significantly shorter OS than others (OS: 19.3 vs. 61.4 months, p = 0.012). Comparison of OS among non-HBV-related-HCC patients without pHBV (group 1), those with pHBV and without hHBsAg+ (group 2), and those with pHBV and hHBsAg+ (group 3) revealed significantly shorter OS in group 3 (19.3, 56.6 and 66.4 months in groups 1, 2 and 3, respectively; p = 0.036). Multivariate Cox regression indicated that compared with group 1, only group 3 was significantly and independently associated with shorter OS (HR: 2.044, p = 0.011). Subgroup analysis revealed that this association was particularly evident in non-HBV-related-HCC patients with non-B-non-C aetiology and advanced HCC. CONCLUSIONS: In non-HBV-related-HCC patients, hHBsAg+, not pHBV, is significantly and independently associated with poor prognosis. - Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Takuya Sho; Goki Suda; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Sonoe Yoshida; Shunichi Hosoda; Koji Ogawa; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Masaru Baba; Yoshiya Yamamoto; Yoko Tsukuda; Takashi Meguro; Ren Yamada; Tomoe Kobayashi; Tomofumi Takagi; Naoya Sakamoto
Targeted oncology, 19, 5, 769, 778, Sep. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: While guidelines recommend immune checkpoint inhibitor (ICI) rechallenge as second-line therapy for unresectable hepatocellular carcinoma (HCC), data supporting this remain limited, particularly regarding a standard regimen for first- and second-line treatments. Tremelimumab/durvalumab was recently approved but data on ICI rechallenge are lacking. OBJECTIVES: The purpose of this study was to evaluate the early efficacy and safety of tremelimumab/durvalumab for HCC as an ICI rechallenge following initial ICI therapy with atezolizumab/bevacizumab. PATIENTS AND METHODS: This multicenter retrospective study included patients with HCC who underwent treatment with tremelimumab/durvalumab, with relevant available clinical information. We evaluated the safety and efficacy of tremelimumab/durvalumab as ICI rechallenge following initial treatment with atezolizumab/bevacizumab. We analyzed the outcomes in patients who underwent tremelimumab/durvalumab as an ICI rechallenge and those who received tremelimumab/durvalumab as their initial ICI therapy RESULT: A total of 45 patients treated with tremelimumab/durvalumab were included, with 55.6% (25/45) undergoing ICI rechallenge. The objective-response and disease-control rates in patients who underwent ICI rechallenge were 14.3% (3/21) and 47.6% (10/21), respectively, similar to those in patients initially treated with tremelimumab/durvalumab. All patients (n = 3) who experienced the best response to progressive disease (PD) with initial atezolizumab/bevacizumab experienced PD during ICI rechallenge. The incidence rates of adverse events were similar between patient groups treated with tremelimumab/durvalumab as ICI rechallenge and initial ICI. Among patients experiencing immune-related adverse events (irAEs) with atezolizumab/bevacizumab, 75% (3/4) encountered similar irAEs during ICI rechallenge. CONCLUSION: Early safety and efficacy profiles of durvalumab/tremelimumab as ICI rechallenge are satisfactory. - 消化器癌における薬物療法の超音波検査による治療効果判定 LEN-TACE療法の治療効果判定における造影USの役割
荘 拓也; 北潟谷 隆; 大原 正嗣; 中井 正人; 須田 剛生; 坂本 直哉
超音波医学, 51, Suppl., S200, S200, (公社)日本超音波医学会, Apr. 2024
Japanese - 非代償性肝硬変の課題克服を目指して 門脈圧亢進症合併HCV症例のSVR後の肝予備能,非代償化の検討
中井 正人; 大原 正嗣; 北潟谷 隆; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉
日本消化器病学会雑誌, 121, 臨増総会, A158, A158, (一財)日本消化器病学会, Mar. 2024
Japanese - 食道胃静脈瘤に対し経皮経脾静脈瘤塞栓術を施行した1例
保浦 直弘; 大原 正嗣; めの 晃光; 甲谷 理紗子; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 阿保 大介; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 46, 46, 日本消化器病学会-北海道支部, Mar. 2024
Japanese - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) deletion in myeloid cells augments cholestatic liver injury.
Anuradha Krishnan; Nazli Begum Ozturk; Kaiyel A Cutshaw; Maria Eugenia Guicciardi; Takashi Kitagataya; Kirsta E Olson; Kevin D Pavelko; William Sherman; Alexander Q Wixom; Nidhi Jalan-Sakrikar; Michelle Baez-Faria; Florencia Gutierrez; Gregory J Gores
Scientific reports, 14, 1, 2145, 2145, 25 Jan. 2024, [International Magazine]
English, Scientific journal, Ductular reactive (DR) cells exacerbate cholestatic liver injury and fibrosis. Herein, we posit that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) emanates from recruited macrophages and restrains DR cell expansion, thereby limiting cholestatic liver injury. Wild type (WT), Trailfl/fl and myeloid-specific Trail deleted (TrailΔmye) C57BL/6 mice were exposed to DDC diet-induced cholestatic liver injury, which induced hepatomegaly and liver injury as compared to control diet-fed mice. However, parameters of liver injury, fibrosis, and inflammation were all increased in the TrailΔmye mice as compared to the WT and Trailfl/fl mice. High dimensional mass cytometry indicated that cholestasis resulted in increased hepatic recruitment of subsets of macrophages and neutrophils in the TrailΔmye mice. Spatial transcriptomics analysis revealed that the PanCK+ cholangiocytes from TrailΔmye mice had increased expression of the known myeloid attractants S100a8, Cxcl5, Cx3cl1, and Cxcl1. Additionally, in situ hybridization of Cxcl1, a potent neutrophil chemoattractant, demonstrated an increased expression in CK19+ cholangiocytes of TrailΔmye mice. Collectively, these data suggest that TRAIL from myeloid cells, particularly macrophages, restrains a subset of DR cells (i.e., Cxcl1 positive cells), limiting liver inflammation and fibrosis. Reprogramming macrophages to express TRAIL may be salutary in cholestasis. - 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Advanced stage肝細胞癌 Phase 3 HIMALAYA試験の結果とその解釈
荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉
肝胆膵, 87, 4, 439, 446, (株)アークメディア, Oct. 2023
Japanese - The results and interpretation of phase III HIMALAYA study
荘拓也; 須田剛生; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 坂本直哉
肝胆膵, 87, 4, 439, 446, (株)アークメディア, Oct. 2023
Japanese - Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
Yoshimasa Tokuchi; Goki Suda; Naoki Kawagishi; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 53, 7, 595, 606, Jul. 2023, [International Magazine]
English, Scientific journal, AIM: Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct-acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify long-term changes in the prevalence of fatty liver and hyper-low-density lipoprotein (LDL) cholesterolemia and their associations in patients who achieve successful HCV eradication using DAAs. METHODS: This retrospective study included patients with HCV who achieved sustained virologic response after interferon-free DAA and analyzed the changes in the prevalence of fatty liver diagnosed with controlled attenuation parameter (CAP), hyper-LDL cholesterolemia, and their relationships at baseline (n = 100) and 24 weeks (SVR24, n = 100), 96 weeks (SVR96, n = 100), and 144 weeks (SVR144, n = 90) after DAA. RESULTS: In 100 participants, the prevalence of fatty liver (19% vs. 32%, p = 0.0349) and hyper-LDL cholesterolemia (6% vs. 15%, p = 0.0379) significantly increased without changes in body weight at SVR96. Median total cholesterol, low-density lipoprotein cholesterol (LDL-C), and small-dense-LDL (sdLDL) levels and CAP values were significantly greater at SVR24, SVR96, and SVR144 than at baseline. Baseline CAP values and changes in CAP values were significantly negatively correlated at every observation point: r = -0.5305, p < 0.0001 at SVR24; r = -0.3617, p = 0.0005 at SVR96; and r = -0.4735, p < 0.0001 at SVR144. A similar relationship was observed in cholesterol levels. Unlike at baseline, CAP values were significantly positively correlated with LDL-C and sdLDL-C levels at all observation points after DAAs. CONCLUSIONS: Direct-acting antivirals may cause an increased prevalence of fatty liver accompanying hyper-LDL cholesterolemia without increased body weight. As post-SVR liver steatosis could cause HCC, careful follow-up may be required. - Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
Masato Nakai; Kenichi Morikawa; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Masatsugu Ohara; Takuya Sho; Goki Suda; Koji Ogawa; Naoya Sakamoto
Journal of gastroenterology, 58, 7, 656, 667, Jul. 2023, [Domestic magazines]
English, Scientific journal, BACKGROUND: Acute kidney injury (AKI) is associated with liver cirrhosis (LC), water retention, diuretics to treat water retention, and a poor prognosis. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) reportedly predicts a poor prognosis in decompensated LC. This study investigated the usefulness of uNGAL in predicting the short- and long-term effects of tolvaptan (TVP) and the incidence of AKI post-TVP administration. METHODS: Of the LC cases with water retention, 86 with available pre-treatment uNGAL were analyzed. A short-term response was defined as weight loss of ≥ 1.5 kg within the first week; a long-term response was defined as a short-term response without early recurrence. The uNGAL usefulness in predicting the short- and long-term effects of TVP and AKI incidence post-TVP administration was investigated. RESULTS: Short-term effects of TVP were observed in 52 patients. Of these, 15 patients had an early recurrence. In multivariate analysis, significant short-term predictive factors were C-reactive protein (CRP) < 1.4 mg/dl, uNa/K ratio ≥ 3.51, and uNGAL < 50.2 ng/ml. Patients were classified according to these three cut-off values, with short-term response rates of 92.9%, 68.8%, 26.7%, and 0% for 0, 1, 2, and 3 points, respectively. CRP < 0.94 mg/dl and uNGAL < 50.2 ng/ml were significant factors for predicting the long-term response of TVP. The AKI incidence post-TVP was 8.1% (n = 7) and was significantly higher among those with uNGAL ≥ 38.1 ng/mL. CONCLUSION: uNGAL is a useful predictor of the short- and long-term efficacy of TVP and can be useful in predicting AKI incidence post-TVP administration. - Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
Risako Kohya; Goki Suda; Masatsugu Ohara; Takashi Sasaki; Tomoka Yoda; Naofumi Sakurai; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Cancers, 15, 12, 20 Jun. 2023, [International Magazine]
English, Scientific journal, Lenvatinib, used for unresectable hepatocellular carcinoma (HCC), causes appetite loss, but the underlying mechanisms, clinical impact, and predictive factors have been unclear. The endocrine factor FGF21 modulates appetite and is involved in cachexia. We evaluated the association between FGF21 level changes during lenvatinib treatment for unresectable HCC and appetite loss. Sixty-three eligible unresectable HCC patients who started lenvatinib treatment between 2018 and 2021 were included. We analyzed FGF21 levels at baseline; 1, 2, and 4 weeks after lenvatinib initiation, and before the onset of appetite loss. Grade ≥ 2 lenvatinib-induced appetite loss led to liver functional reserve deterioration at disease progression and a poor prognosis. Baseline characteristics and serum FGF21 levels were similar between patients with and without appetite loss. However, the serum FGF21 change rate increased significantly at 4 weeks post-lenvatinib initiation in patients with grade ≥ 2 appetite loss, as compared to those without appetite loss. Similar significant increases in the serum FGF21 level change rate were observed prior to grade ≥ 2 appetite loss onset. This suggests that changes in FGF21 levels can be used to predict patients with a greater risk of marked appetite loss and provides insights into the mechanisms underlying lenvatinib-induced appetite loss in patients with HCC. - Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
Takashi Sasaki; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Naoki Kawagishi; Risako Kohya; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Sho Komukai; Koji Ogawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 53, 10, 960, 967, 18 Jun. 2023, [International Magazine]
English, Scientific journal, AIM: Although hepatitis delta virus (HDV) coinfection with hepatitis B virus (HBV) is a global health concern, the global prevalence of HDV infections remains unknown due to insufficient data in many countries. In Japan, HDV prevalence has not been updated for over 20 years. We aimed to investigate the recent prevalence of HDV infections in Japan. METHODS: We screened 1264 consecutive patients with HBV infection at Hokkaido University Hospital between 2006 and 2022. Patients' serums were preserved and subsequently tested for HDV antibody (immunoglobulin-G). Available clinical information was collected and analyzed. We compared the changes in liver fibrosis using the Fibrosis-4 (FIB-4) index between propensity-matched patients with and without the evidence of anti-HDV antibodies and corrected for baseline FIB-4 index, nucleoside/nucleotide analog treatment, alcohol intake, sex, HIV coinfection, liver cirrhosis, and age. RESULTS: After excluding patients without properly stored serums and those lacking appropriate clinical information, 601 patients with HBV were included. Of these, 1.7% of patients had detectable anti-HDV antibodies. Patients with anti-HDV antibody serum positivity had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV coinfection than those who demonstrated serum anti-HDV antibody negativity. A propensity-matched longitudinal analysis revealed that liver fibrosis (FIB-4 index) progressed more rapidly in patients with positive results for anti-HDV antibody tests. CONCLUSIONS: The recent prevalence of HDV infections in Japanese patients with HBV was 1.7% (10/601). These patients experienced rapid liver fibrosis progression, highlighting the importance of routine HDV testing. - Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Shunichi Hosoda; Goki Suda; Takuya Sho; Koji Ogawa; Megumi Kimura; Zijian Yang; Sonoe Yoshida; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
Liver cancer, 12, 2, 156, 170, Jun. 2023, [International Magazine]
English, Scientific journal, INTRODUCTION: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. METHODS: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, 6 weeks after treatment initiation (early PD; n = 13). Of these, 4 patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. RESULTS: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (<333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs. 227 days; HR: 2.41, 95% CI: 1.22-4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. CONCLUSION: Baseline low serum CXCL9 (<333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab. - 免疫チェックポイント阻害剤の奏効率および副作用と腸内環境との関連
杉田 萌々子; 北潟谷 隆; 福島 新弥; 長島 一哲; 山本 碩満; 楊 佳約; 平山 明由; 桂田 武彦; 須田 剛生; 福田 真嗣
腸内細菌学雑誌, 37, 2, 113, 113, (公財)腸内細菌学会, Apr. 2023
Japanese - Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Goki Suda; Masaru Baba; Yoshiya Yamamoto; Takuya Sho; Koji Ogawa; Megumi Kimura; Shunichi Hosoda; Sonoe Yoshida; Akinori Kubo; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Tomoe Kobayashi; Izumi Tsunematsu; Naoya Sakamoto
Journal of medical virology, 95, 2, e28452, Feb. 2023, [International Magazine]
English, Scientific journal, No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has yet been reported. This multicenter prospective study enrolled HBV-carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV-reactivation and received TAF to prevent HBV reactivation-related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation-related hepatitis was evaluated at 6 and 12 months after initiating TAF. Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation-related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous-HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation-related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. TAF could effectively prevent HBV reactivation and HBV reactivation-related hepatitis. - Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Cancers, 15, 3, 18 Jan. 2023, [International Magazine]
English, Scientific journal, The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated. A total of 4, 9, 19, and 14 patients showed CR, PR, SD, and PD, respectively. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Baseline growth factor levels were similar between patients with or without disease control and those with or without an objective response. Growth factor changes between the baseline and the best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies. - Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Naoki Kawagishi; Goki Suda; Yoshiya Yamamoto; Masaru Baba; Ken Furuya; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Viruses, 15, 1, 07 Jan. 2023, [International Magazine]
English, Scientific journal, Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34-6.33; p = 0.007) and baseline Ang2 level ≥ 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level ≥ 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs. - Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
Masatsugu Ohara; Goki Suda; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Frontiers in nutrition, 10, 1272728, 1272728, 2023, [International Magazine]
English, Scientific journal, INTRODUCTION: We aimed to assess the prognostic implications of muscle atrophy and high subcutaneous adipose tissue (SAT) radiodensity in patients with hepatocellular carcinoma (HCC). METHODS: In this retrospective study, muscle atrophy was assessed using the psoas muscle index (PMI) obtained from computed tomography. SAT radiodensity was evaluated based on radiodensity measurements. Survival and multivariate analyses were performed to identify factors associated with prognosis. The impact of muscle atrophy and high SAT radiodensity on prognosis was determined through survival analysis. RESULTS: A total of 201 patients (median age: 71 years; 76.6% male) with HCC were included. Liver cirrhosis was observed in 72.6% of patients, and the predominant Child-Pugh grade was A (77.1%). A total of 33.3% of patients exhibited muscle atrophy based on PMI values, whereas 12.9% had high SAT radiodensity. Kaplan-Meier survival analysis demonstrated that patients with muscle atrophy had significantly poorer prognosis than those without muscle atrophy. Patients with high SAT radiodensity had a significantly worse prognosis than those without it. Muscle atrophy, high SAT radiodensity, the Barcelona Clinic Liver Cancer class B, C, or D, and Child-Pugh score ≥ 6 were significantly associated with overall survival. Further classification of patients into four groups based on the presence or absence of muscle atrophy and high SAT radiodensity revealed that patients with both muscle atrophy and high SAT radiodensity had the poorest prognosis. CONCLUSION: Muscle atrophy and high SAT radiodensity are significantly associated with poor prognosis in patients with HCC. Identifying this high-risk subgroup may facilitate the implementation of targeted interventions, including nutritional therapy and exercise, to potentially improve clinical outcomes. - Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
Ren Yamada; Kenichi Morikawa; Kiyohiko Hotta; Daiki Iwami; Tatsu Tanabe; Sachiyo Murai; Nobuo Shinohara; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Megumi Kimura; Koji Yamamoto; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Journal of viral hepatitis, 29, 11, 976, 985, Nov. 2022, [International Magazine]
English, Scientific journal, Donors with resolved hepatitis B virus (HBV) infection may be a solution for the organ shortage for kidney transplantation (KT). The purpose of this study was to clarify the current state of HBV markers after KT from donors with resolved HBV infection to HBV naïve recipients and the rate of HBV reactivation in recipients with resolved HBV infection. Furthermore, we investigated HBV covalently closed circular DNA (cccDNA) in transplanted organs from donors with resolved HBV infection and the capability of HBV replication in kidney cell lines. We retrospectively analysed the HBV status of 340 consecutive donors and recipients who underwent KT in a single centre. We prospectively measured cccDNA by real-time polymerase chain reaction in kidney biopsy specimens of 32 donors with resolved HBV infection. HBV reactivation was found in three recipients with resolved HBV infection (4.8%, 3/63) after KT. We analysed 45 cases of transplantation from donors with resolved HBV infection to HBV-naive recipients. One case (2.2%, 1/45) became seropositive for hepatitis B core antibody (anti-HBc) and in another case (2.2%, 1/45), HBV-DNA was detected qualitatively in an HBV naive recipient with a donor with resolved HBV infection. In the latter case, cccDNA was measured in the donor kidney during KT. HBV replication was observed in kidney cell lines with HBV plasmid transfection. In conclusion, the risk of reactivation in anti-HBc-positive donors is relatively low. However, post-transplant HBV monitoring should be conducted in all at-risk cases. - Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
Takuya Sho; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Koji Ogawa; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Zijian Yang; Megumi Kimura; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Takuto Miyagishima; Naoya Sakamoto
Cancers, 14, 16, 15 Aug. 2022, [International Magazine]
English, Scientific journal, The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 × 109/L (7/72), Child-Pugh B (9/72), and 2+ proteinuria (8/72). Atezolizumab and bevacizumab therapy was equally effective for patients who did or did not meet the eligibility criteria (PFS, 6.5 vs. 6.9 months, p = 0.765), consistent with subgroup analyses of histories of systemic therapy, platelet counts, Child-Pugh, and proteinuria. Baseline ALBI scores were worse in patients who did not meet the criteria than in those who did and significantly worsened after treatment initiation in patients not meeting the criteria (baseline vs. 12 weeks; 2.35 ± 0.43 vs. −2.18 ± 0.54; p = 0.007). Accordingly, atezolizumab plus bevacizumab was effective for patients not meeting the eligibility criteria of IMbrave150, although careful monitoring for changes in liver functional reserve is needed. - Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma.
Masato Nakai; Kenichi Morikawa; Shunichi Hosoda; Sonoe Yoshida; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Masatsugu Ohara; Takuya Sho; Goki Suda; Koji Ogawa; Naoya Sakamoto
World journal of hepatology, 14, 7, 1480, 1494, 27 Jul. 2022, [International Magazine]
English, Scientific journal, BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC. METHODS: In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative. RESULTS: In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; P < 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients. CONCLUSION: In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC. - Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.
Machiko Umemura; Koji Ogawa; Kenichi Morikawa; Akinori Kubo; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Tomoe Shimazaki; Megumi Kimura; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Kota Ono; Kazumoto Murata; Masaya Sugiyama; Masashi Mizokami; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 52, 7, 586, 596, Jul. 2022, [International Magazine]
English, Scientific journal, BACKGROUND & AIMS: Benefits of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon-lambda3 (IFN-λ3) induction are still not known. This study aimed to investigate the effects of NAs on HBsAg reduction and association with serum IFN-λ3 levels in chronic hepatitis B (CHB) patients. METHODS: A total of 91 patients [51 treated with nucleoside analog entecavir hydrate (ETV) and 40 treated with nucleotide analog adefovir dipivoxil (ADV) or tenofovir disoproxil fumarate (TDF)] with clinically evident CHB (chronic hepatitis, 57; liver cirrhosis, 34) were enrolled in this study. Serum IFN-λ3 levels among patients receiving ETV and ADV/TDF were measured before the initiation of therapy and 1, 3, and 5 years post-therapy. RESULTS: The change (mean ± standard deviation) in serum HBsAg levels from baseline to year five was -0.38 ± 0.46 and -0.84 ± 0.64 log10 IU/ml in ETV and ADV/TDF groups, respectively (p = 0.0004). Higher serum IFN-λ3 levels were observed in ADV/TDF group compared with ETV group during treatment (p < 0.001). Serum IFN-λ3 levels showed negative correlation with HBsAg reduction in ADV/TDF group (r = -0.386, p = 0.038) at week 48. Nucleotide analogs (ADV/TDF) treatment has associated factors with -0.3 log HBsAg decline at 1 year, -0.5 log HBsAg decline at 3 years, and -0.8 log HBsAg decline at 5 years after NAs treatment on multivariate analysis. CONCLUSIONS: Nucleotide analog (ADV/TDF) treatment reduced HBsAg levels greater compared with nucleoside analog (ETV) in parallel with IFN-λ3 induction. - Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
Sonoe Yoshida; Goki Suda; Masatsugu Ohara; Megumi Kimura; Zijian Yang; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 52, 7, 603, 613, Jul. 2022, [International Magazine]
English, Scientific journal, AIM: A high prevalence of overestimated renal function in patients with liver cirrhosis (LC) has been reported; nonetheless, its impact on prognosis remains unclear. We aimed to evaluate the impact of overestimated renal function on prognosis in patients with LC. METHODS: An overestimated renal function was defined as a >20% increase in the creatinine-based estimated glomerular filtration rate (eGFR), compared with cystatin C-based eGFR. LC patients with conserved serum, who were evaluated for muscle atrophy and had proper clinical information were included, and their prognostic factors were analyzed. RESULTS: A total of 215 consecutive patients with LC were included. The prevalence of overestimated renal function was 29.8% (64/215). Kaplan-Meier survival analysis revealed that patients with overestimated renal function had a poorer prognosis than those without overestimated renal function (hazard ratio [HR]: 2.217 95% confidence interval [CI]: 1.290-3.810; p = 0.001). Subgroup analysis showed that overestimated renal function was a significant prognostic factor, irrespective of sex and the presence of hepatocellular carcinoma (HCC). Multivariate Cox regression analyses revealed that overestimated renal function was a significant and independent factor predictive of poor prognosis in the entire cohort (HR: 2.050; 95% CI: 1.041-4.037; p = 0.038) and in subgroups classified by Child-Pugh class A (HR: 2.131; 95% CI: 1.019-4.458; p = 0.044), Model for End-Stage Liver Disease score ≤9 (HR: 2.303; 95% CI: 1.038-5.109; p = 0.04), and presence of HCC (HR: 2.290; 95% CI: 1.128-4.651; p = 0.022). CONCLUSION: Overestimated renal function is a significant and independent prognostic factor in patients with LC. - The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
Akihisa Nakamura; Koji Yamamoto; Rei Takeda; Ren Yamada; Akinori Kubo; Kenichi Morikawa; Sayaka Ando; Tomoe Shimazaki; Takaaki Izumi; Machiko Umemura; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Megumi Kimura; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Toshiro Sugiyama; Hiroshi Takeda; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 52, 6, 508, 521, Jun. 2022, [International Magazine]
English, Scientific journal, BACKGROUND AND AIMS: Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value only in the diagnosis of the advanced fibrosis stage of NASH. In this study, we evaluated soluble CD14 (sCD14) as a diagnostic marker for discriminating NASH from nonalcoholic fatty liver disease (NAFLD) using an animal model and clinical specimens. METHODS: Serum sCD14 levels were measured in samples derived from mice with diet-induced NASH and patients using an enzyme-linked immunosorbent assay. Our cohort enrolled 126 patients with liver needle biopsy-proven NAFLD. RESULTS: The intestinal defense mechanism in NASH model mice was altered as a consequence of the unique gut environment. Elevated serum levels of sCD14 were observed in mice with diet-induced NASH, and the condition of the liver was exacerbated as a result of exposure to gut-derived endotoxin. We confirmed that the serum sCD14 levels in NAFL patients significantly differed from those in NASH patients. The area under the curve for distinguishing between NAFL and NASH was 0.891. Moreover, we found that serum sCD14 levels were weakly correlated with the inflammation grade based on the NAFLD activity score (NAS), the grade of fibrosis according to the Brunt fibrosis classification, and a positive correlation with the grade of ballooning based on NAS in patients with NAFLD. CONCLUSION: sCD14 could be a useful pathophysiological marker and diagnostic adjunct distinguishing NASH from NAFLD. The use of sCD14 may allow the screening and identification of high-risk groups for NASH development and support early therapeutic interventions. - Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
Masato Nakai; Yoshiya Yamamoto; Masaru Baba; Goki Suda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Ken Furuya; Naoya Sakamoto
Scientific reports, 12, 1, 1449, 1449, 27 Jan. 2022, [International Magazine]
English, Scientific journal, Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. This study aimed to clarify the non-invasive factors associated with HCC following sustained virological response (SVR) and to identify the low-risk group. 567 patients without history of HCC who achieved SVR at 24 weeks (SVR24) after IFN-free treatment were retrospectively analyzed. The cumulative incidence of HCC and the risk factors were examined using pre-treatment and SVR24 data. The median observation period was 50.2 months. Thirty cases of HCC were observed, and the 4-year cumulative incidence of HCC was 5.9%. In multivariate analysis, significant pre-treatment factors were age ≥ 71 years (hazard ratio [HR]: 3.402) and LSM ≥ 9.2 kPa (HR: 6.328); SVR24 factors were age ≥ 71 years (HR: 2.689) and LSM ≥ 8.4 kPa (HR: 6.642). In cases with age < 71 years and LSM < 8.4 kPa at the time of SVR24, the 4-year cumulative incidence of HCC was as low as 1.1%. Both pre-treatment LSM (≥ 9.2 kPa) and SVR24 LSM (≥ 8.4 kPa) and age (≥ 71 years) are useful in predicting the risk of HCC after SVR with IFN-free treatment. Identification of low-risk individuals may improve the efficiency of follow-up. - Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Sonoe Yoshida; Shunichi Hosoda; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Cancers, 14, 1, 04 Jan. 2022, [International Magazine]
English, Scientific journal, Serum growth factor changes and their effect on prognosis during lenvatinib for unresectable hepatocellular carcinoma (HCC) remain underexplored. The sequential changes in serum growth factors during lenvatinib for unresectable HCC were evaluated in 58 patients using complete clinical data, and preserved serum was used to investigate changes in FGF-19, ANG-2, HGF, VEGF, and EGF. Patients with a complete response (CR), partial response (PR), and stable disease (SD) were evaluated for growth factor changes between the best response and progressive disease (PD) points, classified based on these changes, and evaluated by post progression survival (PPS). A total of 8, 24, 18, and 8 patients showed CR, PR, SD, and PD, respectively. Multivariate analysis revealed that age, relative dose intensity, and baseline ANG-2 were significantly associated with treatment response. Growth factor changes between the best response and PD points revealed that patients could be classified into four groups based on the EGF, ANG-2, and HGF changes. Although patient characteristics at baseline and PD, their response to lenvatinib, and PFS were similar among those groups, patients with an increase in all growth factors had significantly shorter PPS (median PPS was 553, 323, and 316 versus 173 days in groups 1-4 p = 0.032). We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS. - Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Satoshi Abiko; Kenji Kinoshita; Shuichi Miyamoto; Ryo Sugiura; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
PloS one, 17, 1, e0261760, 2022, [International Magazine]
English, Scientific journal, For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6-12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population. - Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia.
Michiko Takimoto-Sato; Toshinari Miyauchi; Masaru Suzuki; Hideyuki Ujiie; Toshifumi Nomura; Tomoo Ikari; Tomohiko Nakamura; Kei Takahashi; Machiko Matsumoto-Sasaki; Hirokazu Kimura; Hiroki Kimura; Yuichiro Matsui; Takashi Kitagataya; Ren Yamada; Kazuharu Suzuki; Akihisa Nakamura; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto; Naoko Yamaguchi; Noriyuki Otsuka; Utano Tomaru; Satoshi Konno
Frontiers in genetics, 13, 870192, 870192, 2022, [International Magazine]
English, Scientific journal, Background: Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP) is an extremely rare disease caused by mutations in FAM111B, and only approximately 30 cases have been reported worldwide. Some patients develop interstitial pneumonia, which may lead to progressive pulmonary fibrosis and poor prognosis. However, no effective treatment for interstitial pneumonia associated with POIKTMP has been reported. Here, we report an autopsy case of POIKTMP, wherein interstitial pneumonia was improved by corticosteroids. Case Presentation: A 44-year-old Japanese man was referred to our hospital due to poikiloderma, hypotrichosis, and interstitial pneumonia. He developed progressive poikiloderma and muscle weakness since infancy. He also had tendon contractures, short stature, liver cirrhosis, and interstitial pneumonia. Mutation analysis of FAM111B revealed a novel and de novo heterozygous missense mutation, c.1886T > G (p(Phe629Cys)), through which we were able to diagnose the patient with POIKTMP. 3 years after the POIKTMP diagnosis, interstitial pneumonia had worsened. After 2 weeks of administrating 40 mg/day of prednisolone, his symptoms and lung shadows improved. However, he subsequently developed severe hepatic encephalopathy and eventually died of respiratory failure due to bacterial pneumonia and pulmonary edema. Autopsy revealed an unclassifiable pattern of interstitial pneumonia, as well as the presence of fibrosis and fatty degeneration in several organs, including the liver, kidney, skeletal muscle, heart, pancreas, and thyroid. Conclusions: We report a case of POIKTMP in which interstitial pneumonia was improved by corticosteroids, suggesting that corticosteroids could be an option for the treatment of interstitial pneumonia associated with this disease. - Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
Masato Nakai; Goki Suda; Koji Ogawa; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Masatsugu Ohara; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
PloS one, 17, 7, e0270786, 2022, [International Magazine]
English, Scientific journal, Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE). However, the usefulness of rifaximin against CHE is not thoroughly investigated in Japanese patients. We aimed to investigate the efficacy of rifaximin against hyperammonemia and CHE in Japan. We observed 102 patients with HE showing hyperammonemia secondary to LC and examined various biochemical and behavioral parameters following rifaximin treatment. CHE was diagnosed when the patients exhibited two or more abnormal neuropsychological test (NPT) scores but did not indicate OHE symptoms. In the 102 cases, a significant therapeutic effect of rifaximin on hyperammonemia was observed from 2 to 48 weeks after starting treatment. Excluding 10 patients diagnosed with OHE upon starting rifaximin treatment, 12 of the 92 remaining patients (11.8%) transitioned to OHE within 1 year. The 1 year cumulative OHE transition rate was 14.5%. Among the 24 patients with CHE diagnosed by the NPT for whom NPT results could be evaluated at 4 and 12 weeks after starting treatment, 10 (41.6%) had recovered from CHE at 12 weeks. When the factors contributing to recovery from CHE were examined by multivariate analysis, an ammonia level <129 μg/dL was a significant factor. Rifaximin was thus significantly effective against both hyperammonemia and CHE in Japanese patients. - Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
Takuya Sho; Kenichi Morikawa; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Mugumi Kimura; Masato Nakai; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
World journal of gastrointestinal oncology, 13, 12, 2076, 2087, 15 Dec. 2021, [International Magazine]
English, Scientific journal, The phase III clinical trial of the novel molecular targeted agent (MTA) lenvatinib for patients with advanced hepatocellular carcinoma (HCC) (REFLECT trial) found that lenvatinib was non-inferior to sorafenib in overall survival. Recently, the efficacy of multiple MTAs, including lenvatinib, in practice has been reported, and therapeutic strategies for Barcelona Clinic Liver Cancer (BCLC) intermediate stage HCC are undergoing major changes. Based on these results, lenvatinib could be recommended for patients with transcatheter arterial chemoembolization (TACE)-refractory, ALBI grade 1, within the up-to-seven criteria in the BCLC intermediate stage. Lenvatinib provides a more favorable outcome than TACE, even in cases with large or multinodular HCC beyond the up-to-seven criteria with Child-Pugh grade A. When patients meet the definitions of TACE-refractory or TACE-unsuitable, switching to systemic chemotherapy, including lenvatinib, is for favorable for preserving liver function. If initial treatment, including MTA, has a significant therapeutic effect and downstaging of HCC is obtained, additional TACE or surgical resection should be considered. Lenvatinib also has a therapeutic effect for poorly differentiated type and non-simple nodular type HCC thanks to the survival-prolonging effect of this drug. Furthermore, a significant therapeutic effect is expected in tumors with more than 50% liver involvement or main portal vein invasion, which have traditionally been considered to have a poor prognosis in patients. This suggests that at the start of lenvatinib treatment, HCC patients with ALBI grade 1 may be able to maintain liver functional reserve. - Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Taku Shigesawa; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 51, 9, 979, 989, Sep. 2021, [International Magazine]
English, Scientific journal, AIM: A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a real-world setting, with a focus on patients who did not meet the IMbrave150 eligibility criteria. METHODS: In this multicenter study, patients with unresectable HCC treated with atezolizumab plus bevacizumab between October 2020 and May 2021 were screened. In patients who did not meet IMbrave150 eligibility criteria, treatment responses and safety at 6 and 12 weeks were evaluated. RESULTS: Atezolizumab plus bevacizumab was initiated in 64 patients, including 46 patients (71.9%) who did not meet IMbrave150 eligibility criteria. Most of these patients had a history of systemic therapy (44/46). The objective response rate and disease control rate observed using Response Evaluation Criteria in Solid Tumors 1.1 were 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively; these rates were similar between patients who met and did not meet the IMbrave150 criteria. Ten patients experienced progressive disease (PD) at 6 weeks. Portal vein tumor thrombosis was significantly associated with PD (p = 0.039); none of the 15 patients with hepatitis B virus-related HCC experienced PD (p = 0.050). The most common adverse events of grade 3 or higher were aspartate aminotransferase elevation (n = 8, 13.8%) and the safety profile was similar between patients who met and did not meet the IMbrave150 criteria. CONCLUSION: Most patients treated with atezolizumab plus bevacizumab did not meet the IMbrave150 criteria; however, the combination therapy showed good safety and efficacy at the early treatment phase. - Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals.
Yoshimasa Tokuchi; Goki Suda; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Masatsugu Ohara; Ren Yamada; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Scientific reports, 11, 1, 16616, 16616, 16 Aug. 2021, [International Magazine]
English, Scientific journal, We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were recruited into the study. Patients who achieved sustained virological response (SVR); and had complete clinical information, preserved serum samples at baseline and SVR48, and skeletal muscle mass evaluations based on the psoas muscle mass index (PMI) on computed tomography at baseline and ≥ 12 months were included. Altogether, 70.7% of patients (41/58) showed increased PMI after DAA therapy, and mean relative PMI was significantly higher after DAA therapy than at baseline. There were no significant associations between baseline clinical factors routinely examined in clinical practice and increased PMI. Among factors reported to be associated with skeletal muscle loss in patients with chronic liver disease, serum zinc levels and total and free carnitine levels increased significantly after DAA therapy and only changes in serum free carnitine levels were significantly associated with an increased PMI (r = 0305, P = 0.020). In conclusion, increased skeletal muscle mass after successful HCV eradication by DAAs was significantly associated with increased serum-free carnitine levels. L-carnitine supplementation may be beneficial in patients with low skeletal muscle mass after DAA. - Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
Akinori Kubo; Goki Suda; Megumi Kimura; Osamu Maehara; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Cancers, 13, 14, 20 Jul. 2021, [International Magazine]
English, Scientific journal, In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC; however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to lenvatinib, and CTNNB-1 mutation frequency in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. In 52 patients with unresectable HCC treated with lenvatinib, the prevalence of iso-high intensity in the hepatobiliary phase of EOB-MRI was 13%. All patients had multiple HCCs, and 3 patients had multiple HCCs with iso-high intensity in the hepatobiliary phase of EOB-MRI. Lenvatinib response to progression-free survival and overall survival were similar between patients with or without iso-high intensity in the hepatobiliary phase of EOB-MRI. Seven patients (three and four patients who had unresectable HCC with or without iso-high intensity in the hepatobiliary phase of EOB-MRI, respectively) underwent genetic analyses. Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study's findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. - Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia.
Sonoe Yoshida; Goki Suda; Masatsugu Ohara; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Megumi Kimura; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Osamu Maehara; Shunsuke Ohnishi; Naoya Sakamoto
Nutrients, 13, 7, 14 Jul. 2021, [International Magazine]
English, Scientific journal, Renal dysfunction and sarcopenia are important prognostic factors in patients with chronic liver disease (CLD). Muscle atrophy can cause the overestimation of renal function based on serum creatinine. However, the frequency of overestimated renal function in Japanese patients with CLD and its relationship with sarcopenia are unclear. In present study, we evaluated the frequency of overestimated renal function, defined as a >20% higher eGFR using creatinine than using cystatin C, in 307 patients with CLD as well as its relationship with indicators of sarcopenia. In total, 24.8% of patients had overestimated renal function. In a multivariate regression analysis, liver cirrhosis (p = 0.004) and psoas muscle mass index (p = 0.049) were significantly associated with overestimated renal function. Loss of skeletal muscle mass was significantly more frequent in both male and female patients with overestimated renal function than without. In males, the loss of muscle strength and rate of sarcopenia, defined as loss of muscle mass and strength, were significantly higher in patients with than without overestimated renal function. The high frequency of overestimated renal function in Japanese patients suggests that indicators of renal function should be carefully considered; furthermore, monitoring and interventions for both renal function and sarcopenia are needed in patients with CLD. - Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
Yoshimasa Tokuchi; Goki Suda; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Masatsugu Ohara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal of viral hepatitis, 28, 5, 755, 763, May 2021, [International Magazine]
English, Scientific journal, Hepatitis C virus (HCV) infection can cause renal dysfunction, expected to improve upon HCV eradication. However, adverse effects of HCV eradication using direct-acting antiviral agents (DAAs) on renal function have been recently reported. This retrospective study aimed to evaluate renal function with glomerular filtration rate (eGFR) estimated using creatinine (eGFRcre) and cystatin C (eGFRcys). Complete clinical information and preserved serum samples were collected from 207 patients with HCV infection treated with interferon-free DAA at baseline and SVR48 (SVR48). Patients who underwent paired computed tomography (CT) at baseline and ≥12 months after DAA were evaluated for changes in skeletal muscle mass using the psoas muscle mass index (PMI). eGFRcre significantly worsened at SVR48, while eGFRcys was similar at baseline and SVR48. At baseline, eGFRcre was significantly higher than eGFRcys; eGFRcre and eGFRcys were similar at SVR48. Multivariate analysis revealed that the presence of liver cirrhosis and low-albumin level, as well as cirrhosis and age, was significantly associated with the overestimation of renal function by eGFRcre at baseline and SVR48, respectively. In the 57 patients who underwent paired CT at baseline and ≥12 months after DAA, relative values of PMI significantly increased after DAA. After DAA, in patients with increased PMI (65% 37/57), eGFRcre significantly worsened but did not change in patients without increased PMI. eGFRcre significantly worsened after DAAs; however, this might not reflect accurate changes in renal function, partially because of changes in skeletal muscle mass. eGFRcys did not change after DAAs, and it is a potential alternative to eGFRcre. - Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
Naoki Kawagishi; Goki Suda; Megumi Kimura; Osamu Maehara; Ren Yamada; Yoshimasa Tokuchi; Akinori Kubo; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Masatsugu Ohara; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Yusuke Kudo; Mutsumi Nishida; Naoya Sakamoto
Scientific reports, 11, 1, 9207, 9207, 28 Apr. 2021, [International Magazine]
English, Scientific journal, We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associated with non-regression after treatment with direct-acting-antivirals (DAAs). Patients treated with DAAs who underwent transient elastography at baseline and 24 and 96 weeks after DAA therapy were included. Baseline and post-treatment serum Ang2 levels were measured. Liver fibrosis stages were defined based on LSM. Multivariate regression was used to evaluate factors associated with non-regression of liver fibrosis between various time points. In total, 110 patients were included. Of these, 11% showed non-regression of LSM-based fibrosis stage at 96 weeks after DAA therapy. In multivariate analysis, advanced liver fibrosis stage and high baseline Ang2 levels were significantly associated with non-regression at 96 weeks. In patients with advanced liver fibrosis (F3/4), baseline Ang2 levels were associated with non-regression of liver fibrosis stage. Between SVR24 and SVR96, post-treatment Ang2 levels and controlled attenuation parameter values at SVR24 were significantly associated with non-regression of liver fibrosis stage in patients with F3/4. Thus, serum Ang2 levels are an important target for monitoring and therapy. - Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Taku Shigesawa; Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Megumi Kimura; Tomoe Shimazaki; Koji Yamamoto; Ren Yamada; Takashi Kitagataya; Akihisa Nakamura; Kazuharu Suzuki; Masatsugu Ohara; Naoki Kawagishi; Machiko Umemura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Masaya Sugiyama; Masashi Mizokami; Hiroshi Takeda; Naoya Sakamoto
Carcinogenesis, 42, 1, 58, 69, 11 Feb. 2021, [International Magazine]
English, Scientific journal, In hepatocellular carcinoma (HCC), a subset of cells defined by high CD44 and CD133 expression has been reported to possess cancer stem-like cell (CSC) characteristics and to be associated with a poor prognosis. Since the approval of the multikinase inhibitor, lenvatinib, for patients with unresectable HCC, two such inhibitors (sorafenib and lenvatinib) have been employed as first-line systemic chemotherapeutics for these patients. Based on differences in the kinase-affinity profiles between these two drugs, evidence has suggested that both exert different effects on HCC, although these differences are not fully characterized. In this study, using in vitro and a preclinical in vivo xenograft mouse model, we showed that lenvatinib alone (not sorafenib or the cytotoxic agent, 5-fluorouracil) diminished CD44High/CD133High CSCs in HCC. Furthermore, western blotting and reverse transcriptase-polymerase chain reaction analysis revealed that the expression of fibroblast growth factor receptor (FGFR)-1-4 differed between CD44High/CD133High CSCs and control cells. Analysis of the effects of selective FGFR inhibitors and FGFR small interfering RNAs on CSCs in HCC revealed that lenvatinib diminished CSCs in HCC by inhibiting FGFR1-3 signaling, however, FGFR4 signaling was not impacted. Finally, we showed that FGF2 and FGF19 were involved in maintaining CD44High/CD133High CSCs in HCC, potentially, via FGFR1-3. The findings provide novel mechanistic insights into the effects of lenvatinib on CSCs in HCC and provide clues for developing effective targeted therapies against CSCs in HCC. - Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal of gastroenterology, 56, 2, 168, 180, Feb. 2021, [Domestic magazines]
English, Scientific journal, BACKGROUND: Entecavir and tenofovir-disoproxil-fumarate are first-line nucleos(t)ide analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term administration can impact extrahepatic organs. Herein, we sought to examine the effect of NA on lipid metabolism while also characterizing the associated mechanism. METHODS: A retrospective study was performed on HBV patients administered entecavir or tenofovir-disoproxil-fumarate. Patient clinical information, as well as their preserved serum samples obtained at baseline and 6-12 months after treatment initiation, were analyzed. A 1:1 propensity score matching was applied to the assignment of tenofovir-disoproxil-fumarate or entecavir treatment. Changes in serum cholesterol, including oxidized-LDL, were analyzed. Subsequently, in vitro analysis elucidated the mechanism associated with the effect of NAs on lipid metabolism. RESULTS: Administration of tenofovir-disoproxil-fumarate, not entecavir, to chronic HBV patients, decreased serum cholesterol levels, including non-HDL and oxidized-LDL, which are strongly associated with arteriosclerosis. In vitro analysis revealed that tenofovir-disoproxil-fumarate reduced supernatant cholesterol, and upregulated the scavenger receptor, CD36, in hepatocytes. Meanwhile, silencing of hepatic CD36 increased supernatant cholesterol and negated the cholesterol-reducing effect of tenofovir-disoproxil-fumarate in HepG2-cells. Reporter, microarray, and RT-PCR analyses further revealed that tenofovir-disoproxil-fumarate treatment activates PPAR-α-mediated signaling, and upregulates PPAR-α target genes, including CPT1 and CD36. Alternatively, silencing of PPAR-α reversed the effects of tenofovir-disoproxil-fumarate on CD36. CONCLUSIONS: Tenofovir-disoproxil-fumarate modulates lipid metabolism by upregulating hepatic CD36 via PPAR-α activation. Since dyslipidemia could be associated with arteriosclerosis and hepatocarcinogenesis, these discoveries provide novel insights into anti-HBV therapies, as well as the associated extrahepatic effects of NA. - Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Taku Shigesawa; Goki Suda; Megumi Kimura; Osamu Maehara; Yoshimasa Tokuchi; Akinori Kubo; Ren Yamada; Ken Furuya; Masaru Baba; Takashi Kitagataya; Kazuharu Suzuki; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
PloS one, 16, 3, e0247728, 2021, [International Magazine]
English, Scientific journal, A deteriorated liver functional reserve during systemic therapy for unresectable hepatocellular carcinoma (HCC) causes poor patient outcomes. We aimed to identify predictive factors associated with the deterioration of Child-Pugh score at 8 weeks after lenvatinib initiation. Patients with adequate clinical data and baseline preserved serum samples available were included. Baseline fibroblast growth factor (FGF)19 and 21, angiopoietin (ANG)2, and vascular endothelial growth factor (VEGF) levels were evaluated. Thirty-seven patients were included, and 6, 15, 14, and 2 experienced complete response, partial response, stable disease, and progressive disease, respectively. Twenty-four (65%) and 13 (35%) patients showed a maintained/improved and deteriorated Child-Pugh-score, respectively. While baseline clinical data, treatment response, and laboratory data were similar between these two patient groups, baseline ANG2 and VEGF levels were significantly higher (P = 0.0017) and lower (P = 0.0231), respectively, in patients with deteriorated Child-Pugh score than in those without. Based on receiver operating characteristic curve analysis, cut-off values for ANG2 and VEGF were found to be 3,108 pg/mL and 514.9 pg/mL, respectively. Among patients with low VEGF and high ANG2, 89% (8/9) exhibited a deteriorated Child-Pugh score, whereas none of the patients (0/9) with high VEGF and low ANG2 did. The deterioration of the Child-Pugh score in patients with unresectable HCC who are treated with lenvatinib may be predictable based on combined baseline serum ANG2 and VEGF levels. - Durable response without recurrence to Tolvaptan improves long-term survival.
Masato Nakai; Goki Suda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masatsugu Ohara; Machiko Umemura; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal of gastroenterology, 55, 12, 1150, 1161, Dec. 2020, [Domestic magazines]
English, Scientific journal, BACKGROUND: Decompensated liver cirrhosis patients with refractory ascites or pleural effusion have a poor prognosis. Tolvaptan has been used for treating water retention associated with cirrhosis. However, despite the short-term response, water retention recurrence is still observed in some cases. This study aimed to clarify the water retention recurrence rate and the relationship between long-term response without recurrence and prognosis. METHODS: Altogether, 100 patients with decompensated cirrhosis treated with tolvaptan were retrospectively analyzed. Recurrence was evaluated according to the criteria of the EASL clinical practice guideline. The recurrence rate and prognosis of non-responders, patients with recurrence, and long-term responders were analyzed. The baseline factors related to short-term response, recurrence, and long-term response were also evaluated. RESULTS: Approximately 31.0% of the short-term responders had recurrence. Although there was no significant difference in the prognosis by short-term response (p = 0.07), the long-term responders had a significantly better prognosis than those with recurrence and non-responders (p < 0.01). Low CRP levels and high urinary Na/K ratios were significant factors related to short-term response, and the presence of acute kidney injury was also a factor related to non-response. The low CRP level (relapse: < 1.10 mg/dl, long-term response: < 0.94 mg/dl) was identified as a factor related to recurrence and long-term response. CONCLUSION: The long-term responders without recurrence had a significantly better prognosis. CRP was a useful predictor for long-term response, whereas renal function parameters were useful predictors for short-term response. Inflammation control may be important for long-term response and prognosis in cirrhosis patients with water retention. - Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara-Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, Oct. 2020, [International Magazine]
English, Scientific journal, BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. - Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.
Goki Suda; Koji Ogawa; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Masatsugu Ohara; Yoshimasa Tokuchi; Akinori Kubo; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 50, 10, 1196, 1200, Oct. 2020, [International Magazine]
English, Scientific journal, AIM: Coronavirus disease 2019 (COVID-19) is a serious public health concern, with unclarified prevalence in Japan. Concomitant liver disease could increase the severity of COVID-19 disease, and chronic liver disease patients sometimes require frequent admission and gastrointestinal endoscopy. Thus, clarifying the prevalence of asymptomatic COVID-19 in outpatients with liver disease is essential for preventing nosocomial infections. We aimed to clarify the time-dependent changes in COVID-19 seroprevalence in liver disease outpatients, who were asymptomatic for COVID-19, in an area of Japan experiencing a second wave of COVID-19. METHODS: We included the preserved sera of 100, 300, and 300 consecutive liver disease outpatients, who were asymptomatic for COVID-19, from May 2019, March 2020, and May 2020, respectively. The sera were analyzed immunochromatographically to detect immunoglobulin G against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (KURABO) and by Elecsys Anti-SARS-CoV-2-assay (Roche Diagnostics). RESULTS: Analysis of 100 cases from May 2019, before COVID-19 became pandemic, revealed that the specificity of immunochromatographic tests and Elecsys were 98% (95% confidence interval [CI], 93-99.8%) and 100% (95% CI, 97-100%), respectively. Analysis of 300 cases from March 2020 revealed a seroprevalence of 0.3% (1/300; 95% CI, 0-1.8%) for COVID-19 by Elecsys Anti-SARS-CoV-2 assay. Analysis of 300 cases from May 2020 revealed a seroprevalence of 0% (0/300; 95% CI, 0-1.0%). CONCLUSIONS: The Elecsys Anti-SARS-CoV-2 assay has high specificity. The cumulative seroprevalence of COVID-19 by the Elecsys Anti-SARS-CoV-2 assay in outpatients with liver disease in Sapporo, who were asymptomatic for COVID-19, was 0.17% (1/600; 95% CI, 0.0-0.9%) until May 2020. - Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.
Taku Shigesawa; Goki Suda; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
JGH open : an open access journal of gastroenterology and hepatology, 4, 5, 880, 888, Oct. 2020, [International Magazine]
English, Scientific journal, BACKGROUND: Sorafenib and lenvatinib are first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear. METHODS: We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib between August 2009 and January 2019 at the Hokkaido University Hospital. Patients who continued treatment for >2 months, underwent evaluation by computed tomography every 2-3 months, and had complete clinical data were included. Responders were patients with objective response (OR) for lenvatinib and patients with stable disease (SD) exceeding 6 months (long-SD) or OR for sorafenib. The predictive factors for treatment response, including fibroblast growth factor (FGF)19 and 21, angiopoietin 2 (ANG2), hepatocyte growth factor, and vascular endothelial growth factor, were evaluated. RESULTS: Overall, 27 and 29 patients treated with lenvatinib and sorafenib, respectively, were included. The responders for lenvatinib and sorafenib were 63% (17/27) and 38% (11/29), respectively. No significant predictive factors for treatment response were identified in patients treated with sorafenib. However, baseline serum FGF19 and ANG2 levels were significantly associated with treatment response to lenvatinib. All (9/9) patients with low baseline ANG2 and FGF19 levels who received lenvatinib achieved OR. Conversely, the OR was low (13%; 1/9) in patients with high baseline ANG2 and FGF19 levels. Responder rate was 40% (2/5) in patients with high baseline ANG2 and FGF19 levels who received sorafenib. CONCLUSION: This study is, to our knowledge, the first to demonstrate that baseline ANG2 and FGF19 levels may aid in selecting optimal systemic therapy for patients with unresectable HCC. - High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
Naoki Kawagishi; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Yusuke Kudo; Mutsumi Nishida; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 50, 6, 671, 681, Jun. 2020, [International Magazine]
English, Scientific journal, AIM: Factors associated with improvement of liver fibrosis after successful hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting antiviral agents (DAAs) have been not clarified well. Angiopoietin-2 (Ang2) is reported to be associated with vascular leak and inflammation observed in patients with advanced liver fibrosis. METHODS: In this retrospective study, patients treated with IFN-free DAAs who underwent transient elastography before and at 24-weeks post-treatment and achieved sustained viral response were enrolled. Baseline serum Ang2 was measured, and its relationship with other clinical factors was analyzed. Liver fibrosis stage was defined based on liver stiffness according to a previous report. Predictive factors for regression of liver fibrosis stage after DAA therapy were evaluated. RESULTS: Overall, 116 patients were analyzed. Baseline serum Ang2 levels were significantly associated with liver stiffness, spleen index, and liver stiffness-based liver fibrosis stage. Moreover, 75% of patients experienced regression of liver fibrosis stage after DAA therapy. Multivariate analysis revealed that advanced liver fibrosis stage and Ang2 levels were significantly associated with regression of liver fibrosis stage after DAA therapy. In patients with advanced liver fibrosis (F3/4), baseline Ang2 level alone could predict regression of liver fibrosis stage. A baseline Ang2 cut-off value (354 pg/ML) could predict regression of liver fibrosis stage after DAA therapy with high accuracy (sensitivity 0.882, specificity 0.733). CONCLUSIONS: Evaluation of serum Ang2 levels before DAA therapy is important. Our results provide a novel mechanistic insight into non-regression of liver stiffness after DAA therapy. Long-term and larger studies are required. - トルバプタン奏効後の再燃と炎症および尿L-FABP値の関連
中井 正人; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 61, Suppl.1, A347, A347, (一社)日本肝臓学会, Apr. 2020
Japanese - A case of multiple nonsteroidal anti-inflammatory drug-induced diaphragm-like colonic strictures
Hirohito Naruse; Norihiko Shimoyama; Masayoshi Ohno; Takashi Kitagataya; Yoshihiko Shimoda; Jun Itoh; Taiki Kudo; Kazuteru Hatanaka; Yoshiya Yamamoto
Gastroenterological Endoscopy, 60, 4, 1003, 1009, Japan Gastroenterological Endoscopy Society, 01 Apr. 2018
Japanese, Scientific journal - Surgically Diagnosed Primary Hepatic Angiosarcoma.
Seiji Tsunematsu; Shuichi Muto; Hiroki Oi; Tomoaki Naka; Takashi Kitagataya; Rui Sasaki; Yoko Taya; Urara Baba; Yuki Tsukamoto; Kazuhito Uemura; Toshio Kimura; Yukio Ohara
Internal medicine (Tokyo, Japan), 57, 5, 687, 691, 01 Mar. 2018, [Domestic magazines]
English, Scientific journal, Primary hepatic angiosarcoma is a rare tumor originating from endothelial cells in the liver and accounts for approximately 1% of all hepatic malignant tumors. It is difficult to diagnose due to the lack of specific symptoms or tumor markers. No effective treatment exists, but complete surgical resection may achieve a good outcome. Since most primary hepatic angiosarcomas are already at an advanced stage at diagnosis, few reports describe tumors smaller than 2 cm. We report a case of surgery for a 1.7-cm sized primary hepatic angiosarcoma. Further studies are required to improve the preoperative diagnosis of primary hepatic angiosarcoma. - [A case of mixed adenoneuroendocrine carcinoma of the distal bile duct].
Hirohito Naruse; Norihiko Shimoyama; Taiki Kudo; Yoshiya Yamamoto; Kazuteru Hatanaka; Masayoshi Ohno; Jun Itoh; Yoshihiko Shimoda; Takashi Kitagataya
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 115, 6, 544, 553, 2018, [Domestic magazines]
Japanese, Scientific journal, We diagnosed distal cholangiocarcinoma in a 76-year-old woman who was then treated by subtotal stomach-preserving pancreaticoduodenectomy. Histopathological examination revealed a well-differentiated tubular adenocarcinoma on the side of the bile duct, and a neuroendocrine carcinoma in an area outside the bile duct where the tumor had infiltrated. Immunohistochemical staining identified homology between cytokeratins and MUC, indicating a similar origin. This report discusses problems associated with diagnosis and treatment by summarizing 22 patients who underwent curative resection and subsequently had a confirmed prognosis.
- アテゾリズマブ+ベバシズマブ治療によるConversion前後の肝予備能および蛋白尿の変化
荘拓也; 須田剛生; 北野翔一; 目野晃光; 保浦直弘; 北潟谷隆; 大原正嗣; 中井正人; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 33rd, 2026 - 切除不能進行肝細胞癌におけるアテゾリズマブ+ベバシズマブ併用療法の治療効果とTACE併用療法の意義
荘拓也; 須田剛生; 田中崇倫; 北野翔一; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 32nd, 2025 - Hepatitis virus markers
須田剛生; 大原正嗣; 北潟谷隆, 医学のあゆみ, 292, 3, 2025 - 75歳以上の進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果・安全性と肝予備能変化
荘拓也; 須田剛生; 北野翔一; 田中崇倫; 保浦直弘; 目野晃光; 北潟谷隆; 大原正嗣; 中井正人; 坂本直哉, 日本高齢消化器病学会誌, 28, 1, 2025 - 慢性B型肝炎症例におけるCAMP-BとPAGE-Bによる発癌リスク評価の検討
大原正嗣; 須田剛生; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 中井正人; 荘拓也; 坂本直哉, 日本消化器病学会雑誌(Web), 122, 2025 - 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の早期治療効果と安全性
荘拓也; 須田剛生; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 29th, 2024 - The role of contrast-enhanced US in determining the therapeutic effect of LEN-TACE therapy
荘拓也; 北潟谷隆; 大原正嗣; 中井正人; 須田剛生; 坂本直哉, 超音波医学 Supplement, 51, 2024 - 門脈圧亢進症合併HCV症例のSVR後の肝予備能,非代償化の検討
中井正人; 大原正嗣; 北潟谷隆; 荘拓也; 須田剛生; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 121, 2024 - 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の治療効果と安全性の検討
荘拓也; 須田剛生; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 細田峻一; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 小川浩司; 馬場英; 高木智史; 目黒高志; 吉田苑永; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 30th, 2024 - Efficacy and safety of durvalumab and tremelimumab for advanced hepatocellular carcinoma
荘拓也; 須田剛生; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 得地祐匡; 山本義也; 坂本直哉, 肝胆膵, 89, 3, 2024 - 高齢肝疾患患者における筋肉量評価法の検討
大原正嗣; 須田剛生; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 細田峻一; 吉田苑永; 北潟谷隆; 中井正人; 荘拓也; 小川浩司; 坂本直哉, 肝臓, 65, Supplement 1, 2024 - 慢性肝疾患患者の低栄養アセスメントを行うべき患者を適切に絞り込むスクリーニング方法の検討
中井正人; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 荘拓也; 須田剛生; 小川浩司; 坂本直哉, 肝臓, 65, Supplement 1, 2024 - 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の初期治療成績
荘拓也; 須田剛生; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 山本義也; 坂本直哉, 肝臓, 65, Supplement 1, 2024 - 北海道における肝炎ウイルス陽性者対策の課題
大原正嗣; 小川浩司; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 中井正人; 荘拓也; 須田剛生; 坂本直哉, 肝臓, 65, Supplement 2, 2024 - 切除不能肝細胞癌に対するレンバチニブ治療後のFGF21の変化と食欲不振の関連性について
甲谷理紗子; 須田剛生; 大原正嗣; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 中井正人; 荘拓也; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 121, 2024 - 肝硬変性心筋症の頻度と肝硬変症例の臨床経過に与える影響に関する検討
北潟谷隆; 須田剛生; 坂本直哉, 肝臓, 65, Supplement 3, 2024 - 進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法中に自己免疫性脳炎を発症した1例
北野翔一; 荘拓也; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 須田剛生; 坂本直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 135th-129th, 2024 - 門脈圧亢進症症例における低栄養と適切なスクリーニング方法の検討
中井正人; 北野翔一; 田中崇倫; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 荘拓也; 須田剛生; 坂本直哉, 日本門脈圧亢進症学会雑誌, 30, 3 (CD-ROM), 2024 - 切除不能進行肝細胞癌におけるICI-Rechallenge療法の治療効果と安全性の検討
荘拓也; 須田剛生; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 小川浩司; 高木智史; 目黒高志; 馬場英; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 31st, 2024 - 免疫チェックポイント阻害剤の奏効率および副作用と腸内環境との関連
杉田 萌々子; 北潟谷 隆; 福島 新弥; 長島 一哲; 山本 碩満; 楊 佳約; 平山 明由; 桂田 武彦; 須田 剛生; 福田 真嗣, 腸内細菌学雑誌, 37, 2, 113, 113, Apr. 2023
(公財)腸内細菌学会, Japanese - BavenoVI分類とYerdel分類を用いた肝疾患に伴う門脈血栓症に対するアンチトロンビンIII製剤の治療効果の検討
中井 正人; 小川 浩司; 佐々木 貴志; 甲谷 理紗子; 吉田 苑永; 細田 俊一; 得地 祐匡; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉, 日本消化器病学会雑誌, 120, 臨増総会, A417, A417, Mar. 2023
(一財)日本消化器病学会, Japanese - 肝硬変体液貯留に対するトルバプタン投与症例における尿NGAL測定の有用性
中井 正人; 森川 賢一; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 大原 正嗣; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉, 肝臓, 63, Suppl.2, A592, A592, Sep. 2022
(一社)日本肝臓学会, Japanese - 再活性化が疑われた急性E型肝炎の1例
久保 彰則; 小川 浩司; 吉田 苑永; 細田 峻一; 得地 祐匡; 山田 錬; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 石田 勢津子; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 55, 55, Mar. 2022
日本消化器病学会-北海道支部, Japanese - 若年女性に見られた肝細胞腺腫症の1例
北潟谷 隆; 吉田 苑永; 細田 俊一; 久保 彰則; 得地 祐匡; 山田 錬; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 高桑 恵美; 中島 収, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 56, 56, Mar. 2022
日本消化器病学会-北海道支部, Japanese - 肝癌に対する新世代マイクロ波凝固療法の治療成績
中井 正人; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 70, 70, Mar. 2022
日本消化器病学会-北海道支部, Japanese - 当院における切除不能肝細胞癌に対するAtezolizumab+Bevacizumab併用療法の使用経験
吉田 苑永; 荘 拓也; 久保 彰則; 得地 祐匡; 細田 峻一; 北潟谷 隆; 山田 錬; 中井 正人; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 129回・123回, 40, 40, Sep. 2021
日本消化器病学会-北海道支部, Japanese - Lenvatinib加療後にCRに至りconversion surgeryを施行した肝内多発転移を伴う肝細胞癌の1例
細田 峻一; 中井 正人; 吉田 苑永; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 岡崎 ななせ; 大塚 拓也; 三橋 智子, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 129回・123回, 42, 42, Sep. 2021
日本消化器病学会-北海道支部, Japanese - Transient elastographyによるLSMと年齢を用いたSVR後肝発癌低リスク群の囲い込み
中井 正人; 山本 義也; 馬場 英; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 古家 乾; 坂本 直哉, 肝臓, 62, Suppl.2, A543, A543, Sep. 2021
(一社)日本肝臓学会, Japanese - 除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療経験:多施設共同研究
荘 拓也; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 62, Suppl.2, A550, A550, Sep. 2021
(一社)日本肝臓学会, Japanese - 部分的脾動脈塞栓術(PSE)、バルーン閉塞下逆行性経静脈的塞栓術(B-RTO)の肝予備能、線維化マーカー、予後への影響
中井 正人; 小川 浩司; 坂本 直哉; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一, 肝臓, 62, Suppl.1, A332, A332, Apr. 2021
(一社)日本肝臓学会, Japanese - 胆嚢転移を来した原発性肝細胞癌再発の1例
得地 祐匡; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 荘 拓也; 小川 浩司; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 57, 57, Mar. 2021
日本消化器病学会-北海道支部, Japanese - 経過観察中に増大傾向がみられ、肝切除術に至った肝原発神経内分泌腫瘍の1例
久保 彰則; 小川 浩司; 得地 祐匡; 山田 錬; 北潟谷 隆; 重沢 拓; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 58, 58, Mar. 2021
日本消化器病学会-北海道支部, Japanese - 肝機能障害を契機に診断された肝ヘモクロマトーシスの一例
吉田 苑永; 中井 正人; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 67, 67, Mar. 2021
日本消化器病学会-北海道支部, Japanese - 当院における門脈血栓症に対するアンチトロンビンIII製剤の使用成績
北潟谷 隆; 小川 浩司; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 44, 44, Oct. 2020
日本消化器病学会-北海道支部, Japanese - ソホスブビル/ベルパタスビル投与によりSVR12が得られたC型非代償性肝硬変の1例
山田 錬; 小川 浩司; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 45, 45, Oct. 2020
日本消化器病学会-北海道支部, Japanese - 肝性脳症~わが国における現状と課題~ 肝性脳症の疫学
中井 正人; 小川 浩司; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本門脈圧亢進症学会雑誌, 26, 3, 75, 75, Oct. 2020
(一社)日本門脈圧亢進症学会, Japanese - HCC既往の無いC型肝炎SVR後の初発肝発癌の囲い込み因子としての肝弾性度の有用性
中井 正人; 山本 義也; 馬場 英; 古家 乾; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 61, Suppl.2, A682, A682, Sep. 2020
(一社)日本肝臓学会, Japanese - 免疫チェックポイント阻害剤関連肝炎の頻度、予測因子、臨床経過の検討
北潟谷 隆; 須田 剛生; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 61, Suppl.2, A705, A705, Sep. 2020
(一社)日本肝臓学会, Japanese - 進行肝細胞癌に対するREFLECT内/外におけるレンバチニブの治療効果と安全性の検討
荘 拓也; 須田 剛生; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 117, 臨増総会, A253, A253, Jul. 2020
(一財)日本消化器病学会, Japanese - 部分的脾動脈塞栓術(PSE)により肝予備能は改善するか
中井 正人; 小川 浩司; 北潟谷 隆; 山田 錬; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会雑誌, 117, 臨増総会, A367, A367, Jul. 2020
(一財)日本消化器病学会, Japanese - 【最新C型肝炎治療up-to-date】各ゲノタイプにおけるDAA不成功例に対する治療
須田 剛生; 木村 恵; 北潟谷 隆; 重沢 拓; 鈴木 和治; 坂本 直哉, 消化器・肝臓内科, 8, 1, 70, 75, Jul. 2020
(有)科学評論社, Japanese - NAFLD患者におけるMRエラストグラフィ診断能の検討
山田 錬; 小川 浩司; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 61, Suppl.1, A495, A495, Apr. 2020
(一社)日本肝臓学会, Japanese - 進行肝細胞癌に対するレンバチニブ治療成績からみた適格使用時期の検討 多施設共同研究
荘 拓也; 須田 剛生; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 川岸 直樹; 宮城島 拓人; 馬場 英; 古家 乾; 山本 義也; 小林 智絵; 目黒 高志; 高木 智史; 神山 俊哉; 武冨 紹信; 坂本 直哉, 肝臓, 61, Suppl.1, A334, A334, Apr. 2020
(一社)日本肝臓学会, Japanese - 進行肝細胞癌に対するレンバチニブの奏功に寄与する因子と予備能変化についての検討
山田 錬; 荘 拓也; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 60, Suppl.3, A946, A946, Nov. 2019
(一社)日本肝臓学会, Japanese - 門亢症を伴う肝硬変に対する薬物療法の進歩〜腹水・脳症・血栓など〜 リファキシミン投与前後でのNPT改善効果、Bacterial translocationマーカーの検討
中井 正人; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本門脈圧亢進症学会雑誌, 25, 3, 70, 70, Sep. 2019
(一社)日本門脈圧亢進症学会, Japanese - 肝静脈-下大静脈ステント留置にて改善した4型Budd-Chiari症候群の一例
鈴木 和治; 中井 正人; 阿保 大介; 北潟谷 隆; 山田 錬; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 吉野 裕紀; 曽山 武士; 坂本 直哉, 日本門脈圧亢進症学会雑誌, 25, 3, 154, 154, Sep. 2019
(一社)日本門脈圧亢進症学会, Japanese - 増大傾向を認めた肝血管筋脂肪腫の一切除例
北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 折茂 達也; 神山 俊哉; 武冨 紹信; 杉野 弘和; 三橋 智子, 日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 46, 46, Sep. 2019
日本消化器病学会-北海道支部, Japanese - 急速な経過をたどった肉腫様肝癌の1例
山田 錬; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 清水 亜衣; 三橋 智子, 日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 59, 59, Sep. 2019
日本消化器病学会-北海道支部, Japanese - 当院でConversion surgeryを行った膵癌の治療経過
工藤大樹; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 畑中一映; 山本義也; 成瀬宏仁, 膵臓, 33, 3, 2018 - 当院における肝硬変の成因別実態
山本義也; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 成瀬宏仁, 肝臓, 59, Supplement 1, 2018 - C型肝炎に対するDAA治療後の肝細胞癌発生状況
山本義也; 伊藤淳; 北潟谷隆; 霜田佳彦; 大野正芳; 工藤大樹; 畑中一映; 成瀬宏仁, 道南医学会大会並びに総会プログラム・抄録集, 71st, 2018 - 当院における胃静脈瘤出血に対する緊急内視鏡下静脈瘤硬化療法の治療成績
北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 山本義也; 成瀬宏仁, 函館医学誌, 42, 1, 2018 - 異時性に発生した腎癌胆嚢転移の1例
工藤大樹; 成瀬宏仁; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 畑中一映; 山本義也; 下山則彦, 函館医学誌, 42, 1, 2018 - 当院における進行肝癌に対するSorafenib治療増悪後経過の検討
山本義也; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 成瀬宏仁, 肝臓, 59, Supplement 2, 2018 - 当院における切除不能進行胃癌に対するニボルマブの使用経験
畑中一映; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 山本義也; 成瀬宏仁, 日本臨床腫瘍学会学術集会(CD-ROM), 16th, 2018 - C型肝炎に対するDAA治療後の肝細胞癌発生状況
山本義也; 伊藤淳; 北潟谷隆; 霜田佳彦; 大野正芳; 工藤大樹; 畑中一映; 成瀬宏仁, 道南医学会ジャーナル(Web), 1, 2018 - 当科での切除不能膵癌に対するGEM+nab-PTX法の治療成績と予後規定因子の検討
成瀬宏仁; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 山本義也, 日本消化器病学会雑誌(Web), 115, 2018 - 当院におけるBRAF V600E遺伝子変異を有する切除不能進行再発大腸癌の検討
畑中一映; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 山本義也; 成瀬宏仁, 函館医学誌, 42, 1, 2018 - ERCPにおける胆管挿管困難例に対する,膵管ガイドワイヤー法施行後急性膵炎の検討
成瀬宏仁; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 山本義也, 函館医学誌, 42, 1, 2018 - 当院にて手術加療したStage2大腸癌の再発危険因子,予後規定因子と術後補助化学療法の検討
成瀬宏仁; 工藤大樹; 大野正芳; 北潟谷隆; 霜田佳彦; 伊藤淳; 畑中一映; 山本義也, 日本消化器病学会雑誌(Web), 115, 2018 - 遠位胆管癌と診断した乳頭部炎の1例
工藤大樹; 平田甫; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 畑中一映; 山本義也; 成瀬宏仁; 中西一彰; 下田則彦, 日本消化器画像診断研究会プログラム・抄録集, 67th, 2017 - 当科での切除不能胆道癌に対するGEM+CDDP療法の成績と予後予測因子の検討
成瀬宏仁; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 山本義也, 道南医学会大会並びに総会プログラム・抄録集, 70th, 2017 - 慢性偽性腸閉塞の1例
工藤大樹; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 畑中一映; 山本義也; 成瀬宏仁, 道南医学会大会並びに総会プログラム・抄録集, 70th, 2017 - 胃扁平上皮癌の1例
志藤茜; 畑中一映; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 山本義也; 成瀬宏仁, 道南医学会大会並びに総会プログラム・抄録集, 70th, 2017 - 切除不能進行再発胃癌に対するSOX療法の当科治療例の検討
畑中一映; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 山本義也; 成瀬宏仁, 日本癌治療学会学術集会(Web), 55th, 2017 - ERCPにおける胆管挿管困難例に対する,膵管ガイドワイヤー法施行後急性膵炎の検討
成瀬宏仁; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 山本義也, 道南医学会大会並びに総会プログラム・抄録集, 70th, 2017 - 当科における切除不能胆道癌に対するGEM+CDDP(GC)療法の成績と予後予測因子の検討
成瀬宏仁; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 山本義也, 函館医学誌, 41, 1, 2017 - 当科におけるBRAF V600E遺伝子変異大腸癌患者4例の検討
畑中一映; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 山本義也; 成瀬宏仁, 道南医学会大会並びに総会プログラム・抄録集, 70th, 2017 - 当院における下大静脈腫瘍栓を伴う進行肝細胞癌症例の検討
伊藤淳; 山本義也; 霜田佳彦; 北潟谷隆; 大野正芳; 工藤大樹; 畑中一映; 成瀬宏仁, 道南医学会大会並びに総会プログラム・抄録集, 70th, 2017 - C型肝炎に対するDAA治療後の肝細胞癌発生状況
山本義也; 霜田佳彦; 北潟谷隆; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 成瀬宏仁, 道南医学会大会並びに総会プログラム・抄録集, 70th, 2017 - 当院におけるGenotype1b型C型慢性肝疾患に対するインターフェロンフリー療法の治療成績
山本義也; 北潟谷隆; 霜田佳彦; 伊藤淳; 大野正芳; 工藤大樹; 畑中一映; 成瀬宏仁, 函館医学誌, 41, 1, 2017 - 当院におけるヘリコバクターピロリ除菌療法の変遷
大野正芳; 北潟谷隆; 霜田佳彦; 伊藤淳; 工藤大樹; 畑中一映; 山本義也; 成瀬宏仁, 日本ヘリコバクター学会学術集会プログラム・抄録集, 23rd, 2017
- Jun. 2026 - Present
日本門脈圧亢進症学会 - Dec. 2025 - Present
日本肥満学会 - Mar. 2019 - Present
日本肝臓学会 - Jun. 2015 - Present
日本消化器病学会 - May 2014 - Present
日本内科学会 - May 2016
日本消化器内視鏡学会
- 肝細胞癌におけるLSECtin/LAG-3 axisとがん微小環境の関連性の検討と臨床応用
科学研究費助成事業
01 Apr. 2024 - 31 Mar. 2027
北潟谷 隆
日本学術振興会, 若手研究, 北海道大学, 24K18477
